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Role of Stat3 in Regulating HIF-1alpha Expression and Tumor Angiogenesis
Jon Briggs
ABSTRACT

Increased vascularization (angiogenesis) is a required adaptation for sustained
tumor growth, and the primary mediator of de novo blood vessel formation is vascular
endothelial growth factor (VEGF). The central transcriptional activator of VEGF is
hypoxia inducible factor-1 (HIF-1), a heterodimeric transcription factor composed of an
inducible HIF-1α subunit and a constitutively expressed HIF-1β subunit. In addition to
HIF-1, it has recently been reported that signal transducer and activator of transcription 3
(Stat3) is required for VEGF production and angiogenesis. Although it is known that
Stat3 is an important mediator of many of the oncogenic signaling pathways that regulate
HIF-1α, it was not known if Stat3 regulates HIF-1α. To answer this important question,
the effect of blocking Stat3 signaling on both HIF-1α and VEGF expression was
examined. Treatment of cells with IL-6, a potent activator of Stat3, resulted in HIF-1α
and VEGF induction during normoxia. By blocking protein synthesis with
cycloheximide, it was determined that IL-6 induction of HIF-1α resulted from increased
translation. When Stat3 was silenced with siRNA, both basal level expression and IL-6
induction of HIF-1α and VEGF were significantly reduced. Furthermore, it is likely that
Stat3 is required for HIF-1α induction by a variety of growth signals, as both HIF-1α and
VEGF expression resulting from EGF and heregulin were abolished when Stat3 signaling
ix

was blocked. Because we had observed that Stat3 was required for induction of HIF-1α
by growth signals, we wanted to determine if Stat3 was also required for HIF-1α
induction by hypoxia. When stat3 was silenced and cells exposed to hypoxia, HIF-1α
expression was again abolished. Furthermore, the hypoxic induction of VEGF and MMP2 was also prevented. These results, along with loss of basal expression of HIF-1α,
suggest that Stat3 is fundamentally involved with the cellular reponse to hypoxia. This
idea is reinforced by our observation that Stat3 is activated by hypoxia in several cell
lines. These findings position Stat3 as an important target for antiangiogenic therapy, not
only through its direct regulation of the VEGF gene, but also because it is required for
expression of the other most important transcriptional activator of VEGF.

x

INTRODUCTION

Tumor hypoxia and angiogenesis

As solid tumors grow beyond a diameter of 1-2 millimeters, they outgrow the
existing blood supply (52). As a result, areas of low oxygen (hypoxia) develop. The
presence of hypoxic regions was originally hypothesized in response to the observation
that necrosis increased as distance from the vasculature increased (199). Confirmation of
this theory, and more accurate measurements of tumor oxygen levels were achieved with
oxygen electrodes. It was observed that oxygen levels in tumors were highly variable,
with areas as low as 0.7% O2 (206). For their continued growth and survival in a hypoxic
B

B

environment, tumor cells encourage growth of new blood vessels from the pre-existing
vasculature in a process known as angiogenesis (60). It is clear that tumors have an
absolute requirement for vascularization, and in the absence of angiogenesis, sustained
tumor growth cannot occur (59, 60, 87, 118).
In response to hypoxia, cell signaling pathways and transcription factors are
activated in the tumor cells that help them cope with the harsh tumor microenvironment
(87). Activation of these pathways results in changes in gene expression encouraging
survival under conditions of low oxygen, low nutrients, and high acidity. There is
increased need for glucose uptake and metabolism due to low oxygen and nutrients, and
as a result there is increased expression of glucose transporters and glycolytic enzymes.
1

Because it is a toxic environment characterized by hypoxia and acidosis, there is elevated
expression of growth factors and survival pathways. Angiogenesis is facilitated by the
release of soluble factors such as VEGF that bind to receptors on vascular endothelial
cells and encourage their migration and growth. Furthermore, factors are released which
result in the breakdown and restructuring of the extracellular matrix, allowing endothelial
cell migration. In this manner, tumors restructure the local vasculature to fulfill their need
for oxygen and nutrients.
A poor clinical outcome correlates with both microvessel density (118, 216) and
tumor hypoxia (93). The reason for this is that although many tumors are highly
vascularized, the tumor vasculature is often poorly formed and inefficient (24). The
tumor vascular system is characterized by leaky blood vessels, haphazard patterns of
connections, loose attachment, and an abnormal basement membrane (107). These
abnormalities result in a tumor environment that although vascularized, is characterized
by hypoxia, acidosis, and necrosis (107). Tumors with a high degree of hypoxia amount
to a poor prognosis for patients for a variety of reasons. Cells adapted to hypoxia tend to
upregulate genes associated with angiogenesis and metastasis (171). It is clear that
hypoxia exerts selective pressure for formation of a tumor with greater resistance to
apoptosis (77). Furthermore, the environment tends to increase mutation rates (232, 233).
These adaptations result in a tumor with greater potential for survival and metastasis. In
addition, hypoxic tumors tend to have greater resistance to treatment with drugs and
radiation (16, 45, 81). The implication is that tumor cell survival is facilitated by both
encouragement of angiogenesis and adaptation to hypoxia, and therefore tumor
progression correlates with both hypoxia and vascularization.
2

Antiangiogenic therapy was proposed due to the observation that solid tumors
require vascularization for sustained growth (60). By preventing growth of new blood
vessels, the tumor could be deprived of oxygen and nutrients and continued growth
would be inhibited. It is clear that tumors have an absolute requirement for
vascularization, and inhibition of angiogenesis can prevent tumor growth (59, 60, 86, 87,
118). Furthermore, there have been reports of successful clinical trials (115, 226).
Importantly, it has been reported that antiangiogenic therapy in conjunction with
radiation and chemotherapy resulted in an improved response (75, 100, 122, 134, 146,
197). Despite these successful trials, many of the antiangiogenesis inhibitors when used
alone have not been effective (12, 54). A likely explanation for this is that they were not
effective enough, as the majority of them have only targeted an individual angiogenic
factor such as VEGF, and it is known that vascularization is a complex process involving
a variety of factors (54, 118). When drugs are developed with greater potency that are
capable of blocking a wide variety angiogenesis inducers, it is likely that clinical trials
will be more successful either alone or in conjunction with traditional radiation and
chemotherapy (12, 97).

Vascular Endothelial Growth Factor

It had long been known that tumor cells secrete a factor capable of initiating
angiogenesis, however the stimulus responsible for its production was not known (53,
61). Subsequently, it was demonstrated that macrophages exposed to a hypoxic
environment were shown to secrete an angiogenesis-stimulating factor (124). Vascular
3

endothelial growth factor (VEGF) was then purified, sequenced and cloned, leading to its
identification and characterization as an exceptionally potent angiogenic mitogen (117,
135). Following this, it was shown that high VEGF expression occurs close to necrotic
and presumably hypoxic areas, demonstrating probable in vivo stimulation of
angiogenesis by a hypoxic environment (187).
VEGF is a soluble factor capable of stimulating blood vessel growth, and is
important for processes such as embryogenesis and wound repair (52, 54). Furthermore,
it is well established that VEGF is an important mediator of tumor angiogenesis and
progression (53, 84, 151, 162, 187). Tumors with high expression of VEGF have been
shown to be of increased grade and result in a poor clinical outcome (163, 203, 216).
VEGF is demonstrated to be an important therapeutic target in both animal models (9, 97,
101, 103, 121-123, 221, 231) as well as patients (100, 115, 226). It is clear from these
reports that VEGF is essential for tumor angiogenesis, and inhibition of VEGF can
prevent angiogenesis and tumor growth.
The biologically active form of vascular endothelial growth factor is VEGF-A
(54), usually referred to as VEGF, and it forms a 45 kDa homodimer (55). VEGF
undergoes splice variation to form four main variants of the protein denoted by subscript
numbers representing the number of amino acids: VEGF121, VEGF165, VEGF189, and
B

B

B

B

B

B

VEGF206 (96, 202). These different isoforms bind with varying affinities to both the
B

B

extracellular matrix and receptors expressed on most endothelial cells (54). The two
major VEGF RTKs are VEGF receptor 1 (VEGFR-1, Flt-1) and VEGF receptor 2
(VEGFR-2, KDR, FLK) (40, 198). Although both of these receptors are upregulated by

4

hypoxia and important for angiogenesis, VEGFR-2 is the primary mediator of the growth
and angiogenic properties of VEGF (54, 183).

Regulation of VEGF

Regulation of VEGF expression may result from transcriptional, posttranscriptional or translational mechanisms. Increased transcription results from hypoxia
or growth signals and is facilitated by transcription factors such as HIF-1 and Stat3.
Concerning post-transcriptional modification, proteins binding to the 3’-untranslated
region of VEGF mRNA result in its stabilization in response to hypoxia (31, 36, 136,
190). Furthermore, VEGF may be regulated at the translational level by a mechanism
dependent on the PI3K/AKT/mTOR pathway (30, 150).
In addition to hypoxia (187) and acidosis (185), VEGF transcription can be
induced by a variety of soluble factors such as growth factors, cytokines, and hormones.
Examples of these include transforming growth factor-β (TGF-β) (63, 160), tumor
necrosis factor (TNF) (63, 174), platelet-derived growth factor (PDGF) (56, 209),
keratinocyte growth factor (KGF) (63), Interleukin-6 (IL-6) (33, 38), hepatocyte growth
factor (HGF) (235), Interleukin-1β (IL-1β) (139), fibroblast growth factor-2 (FGF-2) (43,
174)), epidermal growth factor (EGF) (32, 63), and insulin-like growth factor 1 IGF-1)
(32, 72). Many of these signals are commonly overexpressed by tumor cells, and result in
paracrine induction of VEGF which is essential for tumor vascularization (84).
Tumor cells often produce high levels of VEGF without any external stimulation.
This results from genetic changes undergone by the tumor cells themselves, such as loss
5

of tumor suppressor function and oncogene overexpression. Concerning tumor
suppressors, loss of von Hippel-Lindau (VHL) gene (102), p53 (120, 154), and
phosphatase and tensin homologue deleted on chromosome 10 (PTEN) (238) are
associated with increased expression of VEGF. In addition to negative regulation by
tumor suppressors, VEGF is upregulated by a variety of receptor and non-receptor
tyrosine kinases. Examples of membrane bound TKs capable of increasing VEGF
production include EGFR (161) and HER2 (133, 161). Various non-receptor TKs also
stimulate VEGF production, examples include c-Srcpp60 (47, 155, 218), v-Src (109, 154),
P

P

and Ras (83, 166) .
The best documented signaling pathways capable of stimulating VEGF
production are PI3K/AKT and the Ras/Raf/MEK/ERK pathway. Many of the growth
signals or genetic alterations responsible for upregulating VEGF expression are
dependent on the kinases PI3K and Akt (32, 110, 133, 209). Furthermore, loss of function
of the tumor suppressor PTEN results in activation of the PI3K/ AKT pathway (85, 189,
222) and increased VEGF expression (238). Concerning the Ras/Raf/MEK/ERK cascade,
VEGF is upregulated by mutant Ras (166), v-Ras (83) and v-Raf (83). Furthermore,
VEGF is required for Ras-mediated tumorigenesis (84).
Increased transcription of the VEGF gene results from activation of a limited set
of transcription factors. The VEGF promoter contains several confirmed transcription
factor binding sites, including HIF-1 (62, 137), Stat3 (159, 214), AP-1 (174), and Sp1
(56, 174, 184), and AP-2 (69, 202). Induction of VEGF by hypoxia involves HIF-1α, and
this process is well characterized (137, 140). Furthermore, it has been demonstrated that
AP-1 becomes activated under hypoxia (173, 227), and possibly contributes to the HIF-1
6

response to hypoxia (1, 35, 130). It has recently been reported that Stat3 and HIF-1α are
both required for maximal VEGF induction by hypoxia (82).

Other angiogenic factors

Angiogenesis is a complex process requiring not only endothelial cell growth and
migration, but also processes involving reorganization of the extracellular matrix and
basement membrane (94). As a result, a variety of factors in addition to VEGF are
required. Several other factors facilitate angiogenesis in a direct manner by stimulating
growth of vascular endothelial cells, these include basic fibroblast growth factor (bFGF,
or FGF-2) (50) and IL-8 (125). Other factors act in an indirect manner by increasing
VEGF production, and these were described in the previous section. In addition to factors
that stimulate endothelial cell growth, others have been described that regulate
angiogenesis in negative manner. An important example of a negative regulator of
angiogenesis is thrombospondin 1 (TSP-1), which functions by inhibiting endothelial cell
proliferation and inducing apoptosis (112, 175). Furthermore, as with VEGF, it has been
reported that many of these factors are regulated in response to hypoxia, including PDGF
(126, 129), IL-8 (44, 224) and bFGF (129) .
In addition to endothelial cell migration and growth, angiogenesis requires
breakdown of the extracellular matrix and basement membranes, allowing endothelial
cells to migrate toward the source of the angiogenic stimulus. Important factors involved
in this process are the matrix metalloproteinase enzymes, in particular MMP-2 (gelatinase
A) and MMP-9 (gelatinase B) (149). It has been demonstrated that MMP-2 is upregulated
7

by hypoxia (128), and is important for tumor angiogenesis (104), as well as invasion and
metastasis (95, 104, 178).

Hypoxia inducible factor

Hypoxia inducible factor 1 (HIF-1) was originally described as a transcription
factor that binds to the 3’-enhancer of the erythropoietin (EPO) gene, a protein important
for synthesis of haemoglobin, upregulating its production in response to hypoxia (182). It
rapidly became apparent that this transcription factor was instrumental in the hypoxic
regulation of cellular processes beyond haemoglobin synthesis, as the enhancer sequence
was still responsive in cells incapable of producing EPO (211). Furthermore, it was
discovered that a common transcriptional complex inducible by hypoxia was involved
with the regulation of a variety of angiogenic factors (71, 73, 140, 181). The
demonstration that HIF-1 was required for VEGF induction by hypoxia confirmed the
importance of HIF-1 in the cellular response to hypoxia (62). A number of subsequent
studies confirmed that HIF-1 was induced by hypoxia and facilitated transcription of an
array of genes essential for angiogenesis (165).
Hypoxia inducible factor is a heterodimeric transcription factor composed of an
alpha and beta subunit (210, 212). Both subunits belong to a family of transcription
factors which contain a basic-helix-loop-helix (bHLH) and Per/Arnt/Sim (PAS) domain
(210), sequences important for dimerization and DNA binding. The HIF-1β subunit, also
known as aryl hydrocarbon nuclear transporter (ARNT), dimerizes with multiple
members of the bHLH-PAS family of TFs (145). Although both subunits are for the most
8

part continuously transcribed, HIF-1α is rapidly degraded under hypoxia and is subjected
to extensive post-translational regulation. On the other hand, HIF-1β is constitutively
expressed and is not subject to regulation by hypoxia (99). Following translocation to the
nucleus, HIF-1 binds to promoters of genes containing hypoxia response elements and
increases their transcription (180) (Figure 1).
The alpha subunit exists in three isoforms, HIF-1α, HIF-2α, and HIF-3α. The
HIF-1α isoform is the best characterized and seems to be the most important in the
cellular response to hypoxia (99). The HIF-2α subunit, also known as endothelial PAS
domain protein 1 (EPAS 1) or HIF-related factor (HRF), shares 48% sequence identity
with HIF-1α, is inducible by hypoxia and binds to the HREs of hypoxia inducible genes
(49, 58, 201, 220). Although HIF-1α and HIF-2α share significant structural and
functional similarities, they appear to be inducible by different stimuli (22) and have
different patterns of tissue distribution (219). The third variant HIF-3α, also known as
inhibitory PAS domain protein (IPAS), undergoes an alternative splicing event which
removes the transactivation domain, and by binding to HIF-1α rather than HIF-1β
functions in a dominant negative manner (143, 144).
It has been estimated that HIF-1 is capable of directly regulating approximately
60 genes (180). These genes can be categorized into several groups based on their
physiological roles, including angiogenesis, growth and apoptosis, ECM metabolism,
oxygen transport and iron metabolism, and energy metabolism (Table 1) (177). Although
expression of some of these genes, such as VEGF, are under the control of HIF-1 in a
wide variety of cell types, many are regulated in a cell-type specific manner (180). As
9

FIGURE 1. Overview of HIF-1α regulation. Under normal oxygen conditions
(normoxia), HIF-1α levels are very low. This is due to the activity of tumor suppressors
such as VHL and p53, which facilitate HIF-1α ubiquitination and degradation by the
proteosome. When oxygen levels are low (hypoxia), interaction with the tumor
suppressors is disrupted and HIF-1α rapidly accumulates. In addition to its stabilization
by hypoxia, HIF-1α levels can increase due to activation of the PI3K-AKT-FRAP growth
signaling pathway. HIF-1α accumulation by growth signaling results from an increased
rate of synthesis.
10

TABLE 1. Examples of HIF-1 target genes.

Angiogenesis

Gene

Function

Reference

VEGF

Vascular endothelial
cell growth
VEGF receptor
Vascular endothelial
cell growth
Vascular endothelial
cell growth

(62)

FLT-1 (VEGFR-1)
FGFs
PDGF

Growth
apoptosis

and Nip3
Insulin-like growth
factor binding
protein 1 (IGFBP-1)

ECM metabolism

Energy metabolism

(68)
(129)
(71, 129)

Apoptosis
(21)
Binds and sequesters (196)
IGF

(UPAR)
urokinase Degradation of ECM
plasminogen
activator receptor
Degradation of ECM
Matrix
metalloproteinase-2
(MMP-2)
Collagen synthesis
Collagen prolyl-4hydroxylase

(78)

Glucose transporter- Glucose transport
1
Glucose metabolism
6-phosphofructo-1kinase
Glucose metabolism
Phosphoglycerate
kinase 1

(46)

Oxygen
transport Transferrin
Transferrin receptor
and iron metabolism
Erythropoietin

(128)

(194)

(181)
(57)

Iron transport protein
(172)
Mediates cellular iron (141, 192)
uptake
Haemoglobin synthesis (182)

Genes in bold have confirmed HIF-1 binding sites, others are inducible by hypoxia and
are suspected to have HIF-1 binding sites.
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many of these genes are important for growth and survival, they are oncogenic and their
disregulation can lead to tumor development and progression. Because of this, HIF-1α is
often overexpressed in a wide variety of cancer types (180).
Because HIF-1 is important for the regulation of so many genes, many of which
are oncogenic proteins, expression and activity of the HIF-1α subunit is tightly
controlled. Although there are some reports of regulation of HIF-1α mRNA (109, 200,
210), the most frequently documented modes of HIF-1 regulation concerns abundance of
the alpha subunit and HIF-1 transcriptional activation. Regulation of HIF-1α levels, as
with all proteins, is determined by the rate of it’s synthesis versus the rate of its
degradation. It is well documented that the rate of synthesis is determined by the activity
of growth signaling pathways, and the rate of degradation by the availability of oxygen.
Transcriptional activation of HIF-1 is controlled by both growth signaling pathways and
oxygen availability. These modes of regulation will be discussed in greater detail in
subsequent sections.
Regulation of HIF-1α levels and activity occur primarily as a result of
postranslational modification, and these modifications include hydroxylation, acetylation,
and phosphorylation. Hydroxylation of multiple residues facilitates the response of HIF1α to hypoxia, and affects both the rate of degradation and the level of transcriptional
activation. This will be discussed in greater detail in the following section. It is known
that HIF-1α is subject to acetylation by the ARD1 acetyltransferase, and this reportedly
facilitates its degradation by increasing interaction with VHL (108). Several residues of
HIF-1α are phosphorylated (152, 169), as treatment with a phosphatase causes the
multiple bands associated with HIF-1α western blot return to the predicted size of 104
12

kDa (152). The function of HIF phosphorylation is not entirely clear (11), but appears to
be facilitated by MAPK and probably results in transcriptional activation by encouraging
interaction with CBP/p300.

Regulation of HIF-1 by hypoxia

The most notable aspect of HIF biology is induction of the alpha subunit during
hypoxia. Under normal oxygen conditions and without stimulation by growth/oncogenic
signals, HIF-1α levels in vitro are very low and usually undetectable. This is due to its
continual and rapid destruction via proteosomal degradation in the presence of O2.
B

B

Degradation of HIF-1α during normoxia is extremely rapid, and the half-life has been
estimated to be less than 5 minutes (98, 210). As the level of O2 decreases, proteosomal
B

B

degradation ceases and HIF-1α protein accumulates. In this manner, HIF-1 is capable of
responding rapidly to changes in O2 concentrations without having to wait for the
B

B

lengthier processes of transcription and translation.
The destruction of HIF-1α in the presence of O2 is facilitated by tumor
B

B

suppressors such as VHL. Loss of VHL, as occurs in von Hippel-Lindau (VHL) disease,
results in normoxic expression of HIF-1α and re-introduction of wildtype VHL
eliminates HIF-1α expression (147). It was determined that VHL physically interacted
with HIF-1α in a region known as the oxygen-dependent degradation domain (ODD),
mediating its ubiquitination and proteosomal degradation (figure 2) (195). Although it
was known that interaction of HIF-1α and VHL only occurred in the presence of O2, and
B

B

this interaction was abolished during hypoxia or treatment with iron chelators such as
13

FIGURE 2. Structure of HIF-1α and regulation by prolyl hydroxylation. The basic
helix-loop-helix (bHLH) domain and Per-Arnt-Sim (PAS) domain are required for
dimerization and DNA binding. There are two transactivation domains, an aminoterminal transactivation domain (TAD-N, or NAD) and a carboxyl-terminal
transactivation domain (TAD-C, or CAD). An asparagine residue in the CAD is subjected
to hydroxylation by the factor inhibiting HIF (FIH), resulting in increased transcriptional
activity during hypoxia. Stability of the alpha subunit is mediated by the oxygen
dependent degradation (ODD) domain. Two prolyl residues within the ODD are
subjected to hydroxylation by the prolyl hydroxylase (PHD) enzymes during normoxia,
which facilitate interaction with the E3 ubiquitin ligase VHL and result in HIF-1α
destruction.
14

CoCl2, it was not known how the actual level of oxygen was sensed. The mechanism of
B

B

oxygen sensing became apparent with the discovery that VHL was only able to interact
with HIF-1α when several critical conserved proline residues within the ODD were in a
hydroxylated state (105, 106, 229). The enzymes responsible for hydroxylation of proline
residues 402 and 564 were found to belong to a group of prolyl hydroxylase domain
containing (PHD) enzymes. It was subsequently determined that there were three nonheme containing iron dependent PHD enzymes that share significant homology and
facilitate HIF-1α hydroxylation (145). During normoxia, the proline residues in the ODD
domain are fully hydroxylated, facilitating interaction with the E3 ubiquitin ligase VHL
and destruction of HIF-1α. As O2 levels decrease, proline hydroxylation also decreases
B

B

and the ability of VHL to interact with HIF-1α is diminished. In this manner, PHD
enzymes control the rate of HIF-1α degradation in response to variations in oxygen
availability.
In addition to stabilization during hypoxia, it was known that HIF-1
transcriptional activity was also elevated during hypoxia (111, 164). It was eventually
determined that this was dependent on the hydroxylation state of asparagine residue 803
in the transactivation domain (TAD) of HIF-1α. The enzyme responsible for its
hydroxylation during hypoxia was determined to be an asparaginyl hydroxylase, also
known as factor inhibiting HIF-1 (FIH-1) (132). During normoxia, the asparagine residue
803 is hydroxylated disrupting interactions between HIF-1α and the transcriptional
coactivator CBP/p300 (10, 48, 90, 131, 132). During hypoxia, asparaginyl hydroxylation
is diminished, and interaction with CBP/p300 is increased. In this manner, both the
amount of HIF-1α protein and its transcriptional activity is elevated during hypoxia.
15

Regulation of HIF-1 by growth signaling

In addition to regulation by changes in oxygen levels, HIF-1α is regulated by
receptor and non-receptor tyrosine kinases activity. Examples of growth signals,
hormones, and cytokines capable of inducing HIF-1α are numerous, and include insulin
(191, 204, 234), insulin-like growth factor-1 (IGF-1) (234), insulin-like growth factor-2
(IGF-2) (51), PDGF (170), EGF (236), HGF (193), TNFα (89), IL-1β (89, 191, 200),
angiotensin-2 (170) and thrombin (74, 170) (Table 2). Not only is HIF-1α induced by
ligand stimulation of membrane bound receptors, multiple studies have shown that
oncogene (TKs and RTKs) overexpression (or overactivtity) can also elevate HIF-1α
levels. Examples of these include HER2NEU (133), Ras (28, 148), v-Src (109).
P

P

In contrast to stabilization of HIF-1α as occurs during hypoxia, its induction by growth
signals has been shown to function by increasing the rate of its synthesis. This was
demonstrated through the use of the translation inhibitor cyclohexamide and pulse
labeling experiments (64, 133, 204). The majority of these studies implicated members of
the kinase cascade involving the tyrosine kinase PI3-kinase (PI3K) and the serinethreonine kinases AKT (protein kinase B) and FRAP (FKBP/rapamycin-associated
protein, also known as mTOR, mammalian target of rapamycin), as critical for this
enhanced rate of translation. The importance of these kinases was demonstrated
repeatedly through the use chemical inhibitors (64, 191, 204, 236) and dominant negative
versions (236). In addition, loss of the tumor suppressor phosphatase and tensin
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TABLE 2. Regulators of HIF-1α expression or function.

Pathway

Effects on HIF-1α

Reference

Ligands of tyrosine EGF
kinase receptors
IGF-1

Increased translation

(236)

Increased translation

(234)

IGF-2

Increased translation

(51)

Insulin

Increased translation

(191, 204, 234)

Heregulin

Increased translation

(133)

PDGF

Increased translation

(170)

Thrombin

Increased translation

(74, 170)

Angiotensin

Increased translation

(170)

MAPK

Increased transactivation

(169)

RAS

Increased translation

(28)

v-Src

Increased translation,
increased transcription

(109)

c-Src

Increased translation

(116)

PI3K/AKT

Increased translation

(64, 191, 204,
236)

PTEN

Decreased translation

(238)

VHL

Increased degradation

(147)

P53

Increased degradation

(167)

Ligands of other
receptors

Oncogenes

Tumor suppressors
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homologue deleted on chromosome 10 (PTEN), a negative regulator of AKT, or
expression of constitutively active AKT also increased levels of HIF-1α (236, 238).
Furthermore, induction of HIF-1α by non-receptor tyrosine kinases such as c-Src (pp60csrc) (116), v-Src (109), and Ras (28, 148) function via increased translation which is
dependent on the PI3K/AKT/FRAP pathway.
The ability of the PI3K/AKT/FRAP kinase cascade to increase the rate of HIF-1α
synthesis probably depends on the ability of FRAP to phosphorylate two important
components of the translational machinery; eIF-4E binding protein 1 (4E-BP1) and p70
S6 kinase (S6K) (11) (Figure 3). Following phosphorylation, 4E-BP1 loses the ability to
inhibit eukaryotic translation initiation factor 4E (eIF-4E), resulting in increased
recruitment of 40S ribosomal subunit to the 5’ cap structure of the mRNA (11). In
addition, phosphorylated FRAP activates S6K which enables activation of the 40S
ribosomal protein S6, resulting in increased transcription of mRNAs with a 5’
polypyrimidine tract (70, 208). The ability of the PI3K/AKT/FRAP kinase cascade to
increase the rate of HIF-1α synthesis is dependent on the presence of the 5’-UTR of the
HIF-1α mRNA, as removal of this sequence abolished the effects of heregulin (133).
In addition to HIF-1α regulation by the PI3K/Akt pathway, it has been reported that
MAPK signaling is instrumental in receptor mediated activation of HIF-1 (64). Although
its role in regulation of HIF-1α is not as well studied as PI3K/AKT, activation of p42/p44
MAPK seems to result in transcriptional activation of HIF-1 (152, 169, 188). Direct
phosphorylation of HIF-1α by MAPK has been reported (152, 169), and the probable
result of HIF-1α phosphorylation is increased transcriptional activation by
18

FIGURE 3. Mechanism of HIF-1α regulation by growth signaling Activation of PI3K
results in a kinase cascade involving AKT and mTOR. Activated mTOR phosphorylates
p70 S6 kinase (S6K) which in turn phosphorylates S6, increasing transcription of
mRNAs with a 5’ polypyrimidine tract. Furthermore, activated mTOR phosphorylates
eIF-4E binding protein 1 (4E-BP1), which consequently loses its ability to inhibit
eukaryotic translation initiation factor 4E (eIF-4E). Unrepressed eIF-4E facilitates
recruitment of 40S ribosomal subunit to the 5’ cap structure of the mRNA.
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disrupting interactions with FIH, the transcriptional suppressor of HIF-1α (11).
Furthermore, several groups have reported MAPK activation by hypoxia in several cell
lines (34, 148, 152), so it is possible that MAPK activity enhances both signal mediated
and hypoxic transcriptional activation of HIF.

Signal transducer and activator of transcription

Signal transducers and activators of transcription (STATs) are a group of
transcription factors that in the unphosphorylated form exist in a latent state in the
cytoplasm (138). STATs undergo tyrosine phosphorylation by a variety of tyrosine
kinases, including both receptor tyrosine kinases (RTKs) and non-receptor TKs (figure
4). Many membrane bound receptors do not have intrinsic tyrosine-kinase activity, and
therefore require the assistance of the Janus Kinase (JAKs) (23). Furthermore, STAT
phosphorylation can result from the activity of non-receptor tyrosine kinases such as Src
and Abl (37, 228). Phosphorylation of a single tyrosine residue near the carboxy terminus
results in homo- or hetero-dimerization via interaction with the Src-homology-2 (SH2)
domain of the other STAT protein (186). Furthermore, several STAT proteins undergo
serine phosphorylation in the carboxy-terminal transactivation domain resulting in
increased transcriptional activity (217). Following tyrosine phosphorylation and
translocation to the nucleus, Stats bind to promoters containing the consensus sequences
TT(N4)AA and TT(N5)AA (179). Stats control a variety of genes, particularly those
B

B

B

B

involved with cell growth, survival, and immune function (230).
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FIGURE 4. Stat3 signaling pathway. Binding of growth factors or cytokines to their
receptors results in activation of intrinsic receptor tyrosine kinase activity or recruitment
and activation of receptor associated kinases such as janus kinase (JAK). The
cytoplasmic tail of the receptor undergoes phosphorylation providing a docking site for
non-phosphorylated latent Stat monomers. Recruited Stats undergo tyrosine
phosphorylation, followed by dimerization and translocation to the nucleus.
Phosphorylated Stat homo- or hetero-dimers bind to and activate promoters of genes
involved with survival, growth, immunity and angiogenesis.
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There are seven isoforms of Stat proteins, Stat1, Stat2, Stat3, Stat4, Stat5a, Stat5b,
and Stat6. Of these different isoforms, Stat1, Stat3, and Stat5 are commonly activated in a
variety of cancers (23). However, because Stat1 is primarily growth suppressive, it is
not likely that it contributes to oncogenesis (19). There is a wealth of evidence to indicate
that Stat3 and Stat5 are important for tumor progression. Stat5 is commonly activated in
and appears to be important for various leukemias (23). On the other hand, Stat3 is
activated in a wide variety of cancer types, including leukemia (76), multiple myeloma
(25), breast cancer (66, 213), head and neck cancer (80), prostate cancer (157) and
melanoma (158).
There is an abundance of evidence defining a critical role for Stat3 in oncogenesis
(15, 17). Transfection of cells with Stat3C, in which substitution of two residues with
cysteine results in spontaneous dimerization and constitutive activity, results in
transformation and tumor formation in nude mice (20). Furthermore, Stat3 is necessary
for cellular transformation mediated by v-Src (18, 205). It is well established that Stat3
signaling contributes to oncogenesis by preventing apoptosis (25, 79, 80) and blocking
Stat3 signaling induces apoptosis in a variety of tumors (25, 80, 158). Inhibition of Stat3
signaling prevents expression of Bcl-xL, an important anti-apoptotic protein (25, 80, 158).
B
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Furthermore, it has also been demonstrated that Stat3 controls cell cycle progression by
regulating D1 (20). These reports and others firmly establish Stat3 as an important
facilitator of oncogenesis.
Although Stat3 itself is not mutated in tumors, it is activated by and required for
the transforming capabilities of many oncogenic proteins. For example, Stat3 is activated
in cells transformed with v-Src and v-Abl oncogenes (37, 228) and is required for the
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transforming ability of v-Src (14, 18, 205). Furthermore, Stat3 is induced by a variety of
cytokines and growth factors commonly over-expressed by cancer cells, including EGF,
PDGF, and IL-6 (14, 25, 80, 157). These reports and others demonstrate that Stat3 is an
important facilitator for many oncogenic proteins.

Stat3 and angiogenesis

There is accumulating evidence that Stat3 is an important facilitator of tumor
angiogenesis. Stat3 activation correlates with VEGF production in a variety of human
cancers, including breast, head and neck, melanoma, and pancreatic cancer cell lines
(159, 214) as well as VEGF mRNA in pancreatic cancer specimens from patients (214).
Furthermore, many of the growth/oncogenic signaling pathways capable of increasing
VEGF production also result in activation of Stat3. For example it has been reported that
activation of both EGFR and Src signaling pathways result in increased production of
VEGF (47, 155, 161, 218), and it is well documented that stimulation of these pathways
results in Stat3 activation (18, 66, 67, 79, 205, 228). These data indicate that there is a
strong correlation between Stat3 activation and VEGF expression in a variety of cancers.
Several publications have shown that Stat3 is required for VEGF expression in
various cancer cell lines. Blocking constitutive Stat3 activity in tumor cells with a
dominant negative version downregulates basal levels of VEGF expression (159, 214).
Furthermore, it has been shown that Stat3 is necessary for VEGF induction resulting from
both growth signals and tyrosine kinases. In cells transformed with v-Src there is high
expression of VEGF and Stat3 activity, and blocking Stat3 significantly reduces VEGF
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levels (159). Induction of VEGF in by IL-6 or glycoprotein (gp) 130 (a subunit of the IL6 receptor) is dependent on Stat3 signaling (65, 215). Furthermore, Stat3 is required for
VEGF induction by oncostatin-M (OSM) in an astroglioma cell line (168).
Transfection with Stat3C results in constitutive Stat3 activation and induces
VEGF expression in both normal fibroblasts and B16 tumor cells (159). Furthermore,
B16 cells transfected with Stat3C demonstrated increased angiogenesis when placed in
matrigel and inserted into C57BL/6 mice (159). A putative Stat3-responsive element
(SRE) sequence spanning –842 to –849 successfully competed with hSIE probe (159) and
itself was able to function as a probe in EMSA (214). Furthermore, VEGF promoter
activation by v-Src and constitutively activated Stat3 was abrogated when this same
sequence was mutated (159, 214). Stat3 binding to the VEGF promoter in vivo was
confirmed by chromatin immunoprecipitation assays in v-Src transformed NIH3T3 cells
(159). These reports establish that Stat3 increases VEGF production by directly binding
to and activating its promoter.
In addition to its effects on VEGF, Stat3 has been implicated as a facilitator of
angiogenesis by other mechanisms. It has recently been demonstrated that Stat3 regulates
expression of both MMP-2 and MMP-9, important facilitators of both angiogenesis and
metastasis (41, 149, 223). It has also been reported that Stat3 is necessary for signaling by
receptors associated with angiogenic ligands, including bFGFR and VEGFR (7, 42, 176).
Furthermore, it has been demonstrated that Stat3 is necessary for the mitogenic effects of
the angiogenic factor PDGF (14). It has also been reported that Stat3 is required for
endothelial cell migration and microvascular tube formation (225). These data implicate
Stat3 as a key facilitator of angiogenesis beyond regulation of VEGF.
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It has recently been reported that there is a combined requirement for both Stat3
and HIF-1 for maximum VEGF induction by hypoxia or Src (82). Through the use of
CHIP assays, the authors show that HIF-1 and Stat3 bind simultaneously to the VEGF
promoter in response to activated Src or the hypoxia mimic CoCl2. They also demonstrate
B

B

that both Stat3 and HIF-1 are required for maximum activity of a luciferase reporter
construct under the control of the VEGF promoter. When either HIF-1 or Stat3 was
blocked with a dominant negative version, there was an equivalent loss of reporter
activity. Furthermore, they show that both HIF-1α and Stat3 coimmunoprecipitate with
each other as well as the transcriptional activator p300. It is not entirely surprising that
they could form a complex on the VEGF promoter, as the HIF-1 binding site spans –985
to –935, and the Stat3 binding site is 86 bp downstream at –849 to –842 (62, 159).
Although the authors demonstrate that both HIF-1α and Stat3 are required for VEGF
expression, they do not show the effects of blocking Stat3 activity on HIF-1α expression.
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OBJECTIVES

The overall objective of the studies conducted in this dissertation was to
investigate the role of Stat3 in regulating tumor angiogenesis, in particular expression of
HIF-1α and VEGF. It had recently been determined that Stat3 is a transcriptional
activator of VEGF, and is essential for angiogenesis (159, 214). However, the role of
Stat3 in regulating HIF-1α, the other main transcriptional regulator of VEGF, had not
been examined. Results from preliminary experiments suggested that blocking Stat3
prevented both basal level expression and the hypoxic induction of HIF-1α. These
findings lead to the hypothesis that Stat3 is required for HIF-1α expression, and blocking
Stat3 signaling could abrogate both tyrosine kinase and hypoxia induced HIF-1 activity
and VEGF expression. In order to verify this hypothesis, the following aims were
pursued.

Aim I. To determine the role of Stat3 in HIF-1α expression induced by growth
signals.

(A) To determine the mechanism by which IL-6 induces HIF-1α expression. It had
been reported that stimulation of a variety of receptor tyrosine kinases results in increased
HIF-1α levels during normoxia (64, 133, 204, 236). However, it had not been determined
if stimulation with IL-6 resulted in elevated levels of HIF-1α. Because Stat3 is an
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important facilitator of IL-6 signaling, the role of Stat3 in IL-6 induced HIF-1α
expression was examined.

(B) To determine if Stat3 is required for HIF-1α induction by oncogenic growth
signals other than IL-6. Multiple growth signals that activate Stat3 also result in
elevated expression of HIF-1α during normoxia. For example, stimulation with
epidermal growth factor (EGF) increases both Stat3 activation and HIF-1α expression
(236, 237). Because it had been observed that Stat3 was required for HIF-1α induction by
IL-6, experiments were performed to determine if Stat3 was also required for increased
HIF-1α expression resulting from heregulin and EGF.

Aim II. To determine the role of Stat3 in the cellular response to hypoxia.

(A) To determine if Stat3 is required for the hypoxic induction of HIF-1α and
hypoxia inducible genes. It has been reported that inhibiting the AKT/PI3K pathway
does not limit the induction of HIF-1α by hypoxia (2, 6). This suggests that expression of
HIF-1α due to growth signaling and hypoxia result from separate and independent
mechanisms. Because it had been observed that blocking Stat3 signaling prevented both
basal HIF-1α expression and its induction by growth signals, experiments were
performed to determine if the hypoxic induction of HIF-1α was also prevented.
Furthermore, the role of Stat3 in the hypoxic induction of VEGF and MMP-2 was
examined.
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(B) To characterize Stat3 activation by hypoxia. HIF-1 is an important regulator of the
VEGF gene in response to hypoxia. Because it has been reported that Stat3 is also a
transcriptional regulator of VEGF, and preliminary experiments in the laboratory
suggested that Stat3 was necessary for HIF-1α induction by hypoxia, Stat3 activation by
hypoxia was examined. Furthermore, the time-course of Stat3 activation in relation to
HIF-1α and VEGF induction was studied.
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MATERIALS AND METHODS

Reagents and antibodies

The following reagents and antibodies were purchased from various companies as
indicated: Interleukin 6 (BD Pharmingen); heregulin (Sigma); EGF (Sigma);
Cyclohexamide (Calbiochem); G418 (Cellgro); CoCl2 (sigma); Anti-VEGF monoclonal
B
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antibody (R&D); Anti-HIF-1α polyclonal antibody and Anti-β-actin monoclonal
antibody (Santa Cruz Biotechnology); Anti-HIF-1β monoclonal antibody (NOVUS
Biologicals); Anti-Phospho-Akt (Cell Signaling). Anti-Akt1 monoclonal antibody was a
kind gift from Dr. J. Cheng (University of South Florida College of Medicine, Tampa).

Cell lines and cell culture

BALB/c-3T3 fibroblasts and v-Src-transformed BALB/c 3T3 fibroblasts were grown in
Dulbecco’s modification of Eagle’s medium (DMEM) with 10% calf serum (CS) and 1%
antibiotic-antimycotic (Gibco). MCF-7, DU-145, and A2058 tumor cells were grown in
RPMI 1640 with 10% FBS and 1% antibiotic-antimycotic. BALB/c fibroblasts were a
gift from Dr. Jack Pledger (H. Lee Moffitt Cancer Center, Tampa, Florida). BALB/c
fibroblasts transformed with v-Src were a gift from Dr. Richard Jove (H. Lee Moffitt
Cancer Center, Tampa, Florida). A2058 human melanoma, DU145 human prostate
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cancer and MCF-7 human breast cancer cells were obtained from ATCC (Rockville,
MD). For culture under hypoxia, cells were placed in a modular incubator chamber
(Billups-Rothenberg). The chamber was sealed and flushed with a gas mixture containing
1% O2, 5% CO2, and 94% N2 for 10-15 minutes, and then incubated at 37°C.
B
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Treatment With Src Tyrosine Kinase Inhibitors

PD166285 (127) and PD180970 (127) were dissolved in 100% dimethyl sulphoxide
(DMSO) and stored at -80oC. The stocks were diluted into the media, immediately prior
P

P

to use.

Generation of cell lines stably transfected with Stat3 siRNA

The Stat3 siRNA oligonucleotide, AATTAAAAAAGTCAGGTTGCTGGTCAAATTCT
CTTGAAATTTGACCAGCAACCTGACTTCC, was inserted into pSilencer 1.0-U6
siRNA expression vector (Ambion). To generate siRNA/Stat3 stable tumor cell clones,
the pSilencer 1.0-U6 Stat3 siRNA expression vector (1ug) was co-transfected with
pcDNA3 (0.1µg) into MCF-7 and A2058 cells using Lipofectamine (Invitrogen) as
described below, followed by selection with hygromycin (300 µg/ml). MCF-7 and
A2058 clones stably transfected with the empty pSilencer/pcDNA3 were used as a
control.
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Retrovirus infection

The stable retrovirus-producing cell lines HEK 293T expressing Stat3D and MSCV (the
control retrovirus vector) were generous gifts from Dr. D. Link (Washington University,
Seattle). For retrovirus infection, supernatant was collected from confluent retrovirusproducing cells following a 48 hour incubation. The supernatant was supplemented with
8 µg/ml polybrene. BALB/c-3T3 v-Src cells were seeded at 1.5 X 106 in a 10cm plate the
P
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day prior to infection. The following day, cells were cultured in viral supernatant for 4-8
hours, then the viral supernatant was replaced with normal growth media. This was
repeated up to three times until 100% infection efficiency had been achieved, as
visualized by fluorescent microscopy.

Anti-sense oligonucleotide and Stat3 siRNA transient transfections

For transfection with antisense oligonucleotide, human tumor cells were seeded in 6-well
plates at 2.5 x 105 or 10cm dishes at 1.5 x 106 for 18-24h prior to transfection. Cells were
P
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transfected with either 1 µg of plasmid DNA or 300 nM oligonucleotide using
Lipofectamine and Lipofectamine plus reagents (Life Technologies), according to the
manufacturer’s protocol. The sequence for Stat3 antisense oligonucleotide was 5’GCTCCAGCATCTGCTGCTTC-3’. The sequence for control oligonucleotide was 5’–
GCTCCAATACCCCGTTGCTTC-3’. For transient transfection with Stat3 or HIF-1α
(Dharmacon), cells were seeded at 2.5 x 105 per well of 6-well plates 18-24h prior to
P

P
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transfection. Cells were transfected with 10-50nM siRNA using transit TKO transfection
reagent (Mirus), according to the manufacturer’s protocol.

Preparation of whole cell and nuclear extracts

For preparation of whole cell extracts, cells were washed 3x with ice cold phosphatebuffered saline (PBS), scraped into PBS and pelleted by centrifugation at 2500 x g for 5
min at 4C. Pellets were resuspended in RIPA triple detergent lysis buffer (50 mM Tris
(pH 7.4), 5 mM EDTA, 150 mM NaCl, and 0.5% Triton-X-100, 1 mM PMSF, 2 µg/ml
leupeptin, 2 µg/ml aprotinin, and 2 µg/ml pepstatin), then incubated on ice for 30 min.
Lysates were centrifuged at 15000 x g for 30 min. Supernatants were collected and
protein concentration was determined using the Bradford assay. For preparation of
nuclear extracts, cells were washed 3x with ice cold PBS (supplemented with 100 mM
Na3VO4, 100 mM NaF), scraped into PBS and pelleted by centrifugation at 2500 x g for 5
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min at 4°C. Pellets were resuspended in hypotonic buffer A (10mM Tris-HCl (pH 7.6),
1.5 mM MgCl2, 10 mM KCl, 2mM DTT, 0.4 mM PMSF, 1mM Na3VO4, 2 µg/ml
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leupeptin, 2 µg/ml aprotinin, and 2 µg/ml pepstatin) then centrifuged at 2500 x g. Cells
were resuspended in buffer A + 1% NP-40 then incubated on ice for 10 min. Cells were
centrifuged for 10 min at 10,000 x g. The supernatant (cytoplasmic extract) was
discarded, and the pellet was resuspended in hypertonic buffer C (0.42 M KCl, 20 mM
Tris-HCl (pH 7.6), 20% glycerol, 1.5 mM MgCl2, 2mM DTT, 0.4 mM PMSF, 1 mM
B
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Na3VO4, 2 µg/ml leupeptin, 2 µg/ml aprotinin, and 2 µg/ml pepstatin). Following
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stirring for 30 min at 4°C, extracts were spun at 15,000 x g for 30 min. Supernatants were
collected (nuclear extract) and concentration was determined using the Bradford assay.

Western Blotting

Equal amounts of whole cell or nuclear extract (30-50 µg of NE or 100 µg of WCE) were
dissolved in Laemmli SDS-PAGE sample buffer (100mM Tris-HCl (pH 6.8), 4% SDS,
0.2% Bromophenol, 20% glycerol, 2% 2-mercaptoethanol, 1mM DTT) and boiled at
100°C for 5 min prior to separation by SDS-polyacrylamide gel electrophoresis. Samples
were applied to 8% polyacrylamide gels for nuclear extracts and 12% polyacrylamide
gels for whole cell extracts. Electrophoresis was generally performed at 50 V for
approximately 16 hours. For transfer, the Gel, PVDF membrane (Millipore), and filter
papers were soaked in transfer buffer (25 mM Tris base, 192 mM glycine, 20 %
Methanol) for approximately 5 min. The gel and membrane were sandwiched between
the filter papers and placed in a semidry electroblotter (Owl Separation Systems).
Transfer was generally performed at 200 mAmps for 4 hours (current varied depending
on gel size, but never exceeded Area (cm) X 3 mAmps). Following transfer, even loading
and transfer was confirmed by staining the membrane with Ponceau S solution (Sigma).
The membrane was blocked by incubation for 1 hour at room temperature in blocking
buffer (PBS containing 5% non-fat dry milk and 0.1% Tween). Membranes were probed
with primary antibody dissolved in blocking buffer at the following concentrations: HIF1α rabbit polyclonal (H-206) (1:500 dilution), HIF-1β mouse monoclonal (1:1,500
dilution), B-actin mouse monoclonal (1:5000), AKT1 mouse monoclonal (1:1,000
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dilution), phospho-AKT rabbit polyclonal (1:1,000 dilution), and VEGF mouse
monoclonal antibody (1:500 dilution). Probing with primary antibodies was performed
for 3 hours at room temperature or overnight at 4°C. Membranes were washed with
washing buffer (PBS with 0.1% Tween) twice for 5-10 min each. Membranes were
probed with secondary antibody dissolved in blocking buffer at the following
concentrations for one hour: Horseradish peroxidase-conjugated sheep anti-mouse
(1:2,500) and donkey anti-rabbit (1:5,000). Following incubation with secondary
antibody, membranes were washed with washing buffer for 15 min three times. The
signal was developed with SuperSignal West Pico Chemiluminescent Substrate
(PIERCE) according to manufacturer’s instructions.

Electrophoretic Mobility Shift Assay (EMSA)

Binding reactions were carried out in a total volume of 20ul containing 4-8 µg of
normalized nuclear extract in (10 mM HEPES, 10% glycerol, 1 mM DTT, 0.1µg/µl poly
(dI:dC), 0.5 g/ul BSA, 80mM NaCl). The 32P-radiolabeled hSIE (Stat3 and Stat1 specific
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high affinity Sis-Inducible Element, 5’-AGCTTCATTTCCCGTAAATCCCTA) probe
was added and samples were incubated for 30 min at 30°C. Following the binding
reaction, protein-DNA complexes were resolved by 5% non-denaturing polyacrylamide
gel electrophoresis (PAGE). Electrophoresis was carried out at 200 V in 0.25 X Trisborate-EDTA (TBE) (1x TBE is 89 mM Tris-HCl, 89 mM boric acid, and 5 mM EDTA)
for 2-3 hours. Gels were fixed with fixing buffer (10% Methanol, 10% acetic acid),
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vacuum dried at 80°C for 2 h, and autoradiographed with intensifying screens at –80°C
for 1 to 5 days

RNA isolation and Northern blotting

Total RNA was isolated (from 1.5 x 106 cells seeded in 10-cm dishes) using TRIzol
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reagent (Invitrogen) according to the manufacturer’s instructions. 15-µg aliquots were
added to 15ul loading buffer (Sigma) and samples were denatured at 65°C for 15 min.
Samples were loaded into a 1% agarose-formaldehyde gel (containing ethidium bromide)
and electrophoresed at 80 volts for approximately 5 hours in 1X MOPS (10X Mops is 0.4
M Morpholinopropanesulfonic acid, 0.1 M Sodium acetate–3 H2O, 10 mM EDTA-Na2-2
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H2O, pH 7.2) solution. Prior to transfer, the gel was photographed under UV light to
B

B

verify equal loading by visualization of the 18S and 28S rRNA bands. The gel, nylon
membrane (PerkinElmer), and whatman filter paper were presoaked in 10X SSC prior to
transfer. RNA was transferred to membrane in 10x standard saline citrate (SSC) by
upward capillary transfer. The membrane was washed briefly in 2X SSC and ultra-violet
cross-crosslinked using a UV-Stratalinker 2400 (Stratagene, La Jolla, CA, USA).
For preparation of the HIF-1α probe, the entire HIF-1α cDNA (3.2 Kbp) was 32PP
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radiolabeled using All-in-OneTM random primer DNA labeling mix (-dATP) (Sigma)
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according to the manufacturer’s protocol. The radiolabeled cDNA was purified using a
G-25 sephadex column (Roche) according to the manufacturer’s protocol. To detect the
HIF-1α transcript, the membrane was first pre-hybridized at 68°C for at least 5 min in
hybridization buffer (Sigma). The radiolabelled cDNA was denatured by heating to
35

100°C for 10 min followed by placement on ice for 2 min. The denatured probe was
added to the warm pre-hybridization solution, and the membrane was hybridized
overnight at 42°C. The following day, the membrane was washed at least twice at 60°C
with 2x SSC for 15 min, and then exposed to a phosphoimaging plate for 3 hours
(Molecular Dynamics).
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RESULTS

Aim I: To determine the role of Stat3 in HIF-1α expression induced by growth
signals.

IL-6 increases levels of HIF-1α protein

Multiple studies have shown that HIF-1α expression is increased by a variety of
growth/oncogenic signals. Examples of these signals include heregulin (133), EGF (236),
IGF-1 (234), TNFα (89), IL-1β (89, 191, 200) and others. In addition to HIF-1α, many of
these signals also increase expression of VEGF (32, 63, 139, 174). Although it has been
reported that stimulation with IL-6 results in increased production of VEGF (33, 38), it
has not been demonstrated that it increases HIF-1α expression.
Here we demonstrate that stimulation of MCF-7 human breast cancer with IL-6
results in increased expression of HIF-1α protein in a dose dependent manner (Figure 5).
MCF-7 cells were serum starved for 20 hours followed by stimulation with IL-6 in serum
free media at the indicated concentrations for 6 hours. Nuclear extracts were collected
and western blot analysis was performed. Nuclear extracts are used throughout this
dissertation for the detection of HIF-1α by Western blot. Although HIF-1α can be
detected using whole cell extracts, levels are low and the bands are often weak due to the
extremely short half-life of HIF-1α under normoxia. Band intensity and broadness is
significantly increased through the use of nuclear extracts.
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FIGURE 5. IL-6 increases HIF-1α protein in MCF-7 breast cancer cells. MCF-7
cells (1.5 x 106) were cultured for 20h in serum free media followed by treatment with
IL-6 in serum free media at the indicated concentrations for 6h. Nuclear extracts (30ug)
were analyzed by western blotting using the indicated antibodies. HIF-1β and β-actin are
used to verify equal loading.
P
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The vast majority of reports concerning HIF-1α regulation by growth signals and
cytokines indicate that increased expression of HIF-1α occurs without a concurrent
increase in mRNA (11), however exceptions have been reported (200). To determine if
this was true for IL-6, total RNA was collected from MCF-7 cells following treatment
with IL-6 for 6h and analyzed by Northern blotting (Figure 6). Results demonstrate that
the increase in HIF-1α levels resulting from IL-6 stimulation of MCF-7 cells cannot be
accounted for by changes in levels of mRNA.

IL-6 increases HIF-1α expression by increasing its rate of synthesis

A majority of studies show that increased expression of HIF-1α resulting from
stimulation with growth/oncogenic signals is due to an increase in the rate of its
synthesis. Examples include heregulin (133), insulin (204), and IGF-1 (64), in which the
authors directly show that elevated levels of HIF-1α were the result of an increased rate
of synthesis. This was demonstrated through the use of the translation inhibitor
cyclohexamide (CHX) and/or pulse labeling experiments. In contrast, increased HIF-1α
expression resulting from hypoxia is due to protein stabilization, or cessation of the
continuous degradation that occurs during normoxia.
To determine if IL-6 stimulation results in an increased rate of HIF-1α synthesis
or in a decreased rate of degradation, cyclohexamide was utilized. If IL-6 stimulation
stabilizes HIF-1α protein, the addition of cyclohexamide to halt protein synthesis
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FIGURE 6. IL-6 does not increase HIF-1α mRNA in MCF-7 breast cancer cells.
MCF-7 cells (1.5 x 106) were cultured for 20h in serum free media followed by treatment
with IL-6 in serum free media at the indicated concentrations for 6h. RNA (15ug) was
analyzed by Northern blotting using a HIF-1α cDNA probe. A photograph of the
ethidium bromide-stained gel indicates equal loading as demonstrated by the 18S and 28S
rRNA bands.
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following pre-treatment with IL-6 would not affect levels of HIF-1α. However, if IL-6
increases the rate of HIF-1α synthesis, then the addition of CHX would counteract this
and a rapid loss of HIF-1α protein would occur. To determine which of these was
occurring, MCF-7 cells were treated with IL-6 for 6h followed by extraction of nuclear
proteins and Western blot analysis (Figure 7). HIF-1α levels were significantly decreased
as soon as 15 min following addition of CHX and returned to baseline within 1 hour,
demonstrating that increased HIF-1α expression resulting from IL-6 stimulation is due to
an increased rate of synthesis.

Stat3 is required for IL-6 induction of HIF-1α

Many of the growth/oncogenic signals that increase HIF-1α expression also result
in activation of Stat3. It is well established that Stat3 is activated in response to
stimulation with IL-6 (237). Furthermore, it has been reported that IL-6 results in
increased production of VEGF (33, 38) and Stat3 is essential for this effect (215). We
have shown here that IL-6 stimulation upregulates HIF-1α expression by increasing the
rate of its synthesis. Because it was known that blocking Stat3 signaling prevented VEGF
induction by IL-6 (215), as well as tumor angiogenesis (159, 214), we wanted to
determine if HIF-1α expression resulting from IL-6 stimulation was also dependent on
Stat3 signaling.
MCF-7 cells were stably transfected with pSilencer expressing Stat3 siRNA, or
with empty pSilencer. These cells were treated with IL-6 for 6 hours in duplicate and
both whole cell and nuclear extracts were collected. Western blot analysis was performed
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FIGURE 7. IL-6 induced HIF-1α levels are due to synthesis and not cessation of
degradation. MCF-7cells (1.5 x 106) were cultured for 20h in serum free media followed
by treatment with IL-6 (20 ng/ml) in serum free media for 6h. Cyclohexamide (100µM)
was added for the indicated times. Nuclear extracts (30µg) were analyzed by western
blotting using the indicated antibodies. HIF-1β and β-actin are used to verify equal
loading.
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to determine the levels of HIF-1α and VEGF. Results indicate that when Stat3 is silenced
in MCF-7 cells, levels of HIF-1α are significantly lower compared to the control in both
untreated and IL-6 treated cells (Figure 8). Furthermore, VEGF levels are dramatically
reduced both at the basal level and following induction by IL-6 (Figure 8).
It is well documented that induction of HIF-1α by growth/oncogenic signals is
due to increased synthesis. Furthermore, this increased rate of synthesis is the result of
activation of growth signaling pathways, in particular the PI3K/AKT pathway (11). It is
known that stimulation with IL-6 results in PI3K/AKT activation (88). Also, through
correspondence with Dr. J. Cheng (University of South Florida College of Medicine,
Tampa), we learned that Stat3 is a direct transcriptional activator of the AKT-1 gene.
This suggested to us the potential mechanism that Stat3 may be regulating HIF-1α
induction by controlling expression of AKT-1.
To determine if Stat3 regulates Akt expression in MCF-7 cells, both total levels of
Akt1 and phosphorylated levels of Akt1 and Akt2 were examined in cells stably
transfected with Stat3 siRNA. Treatment with IL-6 resulted in increased levels of total
Akt1 and phosphorylated Akt1 and Akt2 (figure 9). Following silencing of Stat3, basal
levels of Akt1 as well as its induction by IL-6 was abolished. Furthermore,
phosphorylated levels of both Akt1 and Akt2 were dramatically reduced. These results
suggest a potential mechanism by which Stat3 regulates HIF-1α expression.
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FIGURE 8. Silencing Stat3 blocks IL-6 induction of HIF-1α. MCF-7 cells were
stably-transfected with empty pSilencer/pcDNA3 or pSilencer/pcDNA3 with Stat3
siRNA. Cells were serum starved for 20h followed by treatment with or without IL-6 (20
ng/ml). Nuclear extracts (30µg) (Top panel) and whole cell extracts (100µg) (middle
panel) were analyzed by Western blotting using the indicated antibodies. Stat3 DNA
binding was determined by EMSA using nuclear extracts (8ug) (bottom panel).
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FIGURE 9. Silencing Stat3 decreases AKT levels. MCF-7 cells (1.5 x 106), stablytransfected with empty pSilencer or pSilencer-Stat3 siRNA, were cultured in serum free
media for 20h followed by treatment with IL-6 for 6h. Whole cell extracts (100µg) were
obtained and analyzed by Western blotting using the indicated antibodies. The antibody
used for detecting phospho-Akt (pAkt) recognizes both Akt1 and Akt2. For the total Akt
protein detection, the antibody is specific for Akt1.
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Stat3 is required for HIF-1α induction by Heregulin

Many growth signals capable of activating Stat3 also increase expression of HIF1α. Examples of these include EGF (236, 237) and PDGF (64, 170, 207). Because we
have observed that blocking Stat3 limits the ability of IL-6 to induce HIF-1α, we wanted
to know if induction of HIF-1α by other growth signals was also prevented when Stat3
was silenced.
Comparable to published results (133), we observed a dose dependent induction
of HIF-1α when MCF-7 cells were stimulated with heregulin for 6h (Figure 10).
Furthermore, coordinate Stat3 activation was observed as determined by EMSA. To
determine if Stat3 is required for HIF-1α induction by heregulin, MCF-7 cells expressing
Stat3 siRNA were again utilized. Following stimulation with heregulin for 6h, HIF-1α
was induced in control cells but not in Stat3 siRNA cells (Figure 11). Furthermore,
VEGF expression was increased by stimulation with heregulin only in control cells. As
previously seen in MCF-7 cells, basal level expression of both HIF-1α and VEGF was
blocked. These data show that Stat3 is required for the induction of both HIF-1α and
VEGF by heregulin in MCF-7 breast cancer cells.

Stat3 is required for HIF-1α induction by EGF

In addition to heregulin, it has been reported that stimulation with EGF results in
both increased HIF-1α expression (236) and Stat3 activation (237). Because we had
observed that silencing Stat3 prevented the induction of HIF-1α by Heregulin and IL-6,
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FIGURE 10. Heregulin increases both Stat3 binding and HIF-1α protein in MCF-7
breast cancer cells. MCF-7 cells (1.5 x 106) were cultured for 20h in serum free media
followed by treatment with heregulin at the indicated concentrations for 6h. Nuclear
extracts (30µg) were analyzed by western blotting using the indicated antibodies. Stat3
DNA binding was determined by EMSA using nuclear extracts (8ug) (bottom panel).
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FIGURE 11. Stat3 siRNA blocks heregulin induced HIF-1α expression. MCF-7 cells
were stably-transfected with empty pSilencer/pcDNA3 or pSilencer/pcDNA3 containing
Stat3 siRNA. Cells were serum starved for 20h followed by treatment with or without
heregulin (100ng/ml). Nuclear extracts (30µg) (Top panel) and whole cell extracts
(100µg) (middle panel) were analyzed by Western blotting using the indicated antibodies.
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FIGURE 12. EGF increases both Stat3 binding and HIF-1α protein in prostate
tumor cell line DU-145. DU-145 cells (1.5 x 106) were cultured for 20h in serum free
media followed by treatment with EGF at the indicated concentrations for 6h. Nuclear
extracts (30µg) were analyzed by western blotting using the indicated antibodies. Stat3
DNA binding was determined by EMSA using nuclear extracts (8ug) (bottom panel).
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we wanted to know if this was also true for EGF. To verify that EGF induced both HIF1α and Stat3 expression in DU145 prostate cancer, cells were treated with various
concentrations of EGF for 6h. Consistent with previous reports (236), treatment with
EGF results in increased expression of HIF-1α, as well as significant activation of Stat3
(Figure 12). To determine if knocking down Stat3 expression could prevent induction of
HIF-1α by EGF, antisense oligonucleotide was utilized. Following transfection with
ASO, cells were treated with EGF for 6 hours and nuclear extracts were obtained for
Western blot analysis. Results demonstrate that transfection of cells with ASO results in
significantly diminished levels of HIF-1α in both nontreated and EGF treated samples.
(Figure 13). These results and those described in previous sections show that Stat3
signaling is necessary for both basal expression of HIF-1α and for its induction by
growth signals and cytokines.

Aim II. To determine the role of Stat3 in the cellular response to hypoxia.

Stat3 is required for HIF-1α induction by hypoxia

It is well documented that increased levels of HIF-1α resulting from growth
signals are due to increased synthesis, and increased levels by hypoxia result from
stabilization and therefore accumulation. It is also reported that both hypoxic stabilization
and growth signal induced translation can increase HIF-1α levels in a cumulative
manner. However, several studies indicate that blocking the PI3K/AKT pathway does not
limit the ability of hypoxia to increase HIF-1α levels (2, 6, 113). If silencing Stat3
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FIGURE 13. Stat3 is required for EGF mediated HIF-1α expression. DU-145 cells
were transiently transfected with control or Stat3 ASO, serum starved for 20h followed
by treatment with EGF (30ng/ml) for 6h. Nuclear extracts (30ug) were analyzed by
Western blotting using the indicated antibodies.
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decreases HIF-1α levels only by affecting AKT, then blocking Stat3 signaling should not
affect HIF-1α induction by hypoxia. However, if silencing Stat3 also limits HIF-1α
induction by hypoxia, then there is likely some other mechanism also at work. Because
we had proposed that Stat3 regulates HIF-1α via AKT, we wanted to know if blocking
Stat3 signaling could prevent the induction of HIF-1α by hypoxia.
Our initial experiments involving HIF-1α induction by hypoxia utilized BALB/c3T3 fibroblasts transformed by the oncoprotein v-Src. These cells have high levels of
Stat3 activation as well as HIF-1α expression during normoxia (figure 14). The multiple
bands associated with HIF-1α in this figure result from post-translational modifications.
When they were transduced with retrovirus carrying the dominant negative Stat3D or
empty vector MSCV, Stat3 DNA binding was almost completely ablated. Furthermore
HIF-1α expression resulting from v-Src activity was eliminated. When these cells were
treated with the hypoxia mimic CoCl2, HIF-1α expression was strongly induced in the
B

B

MSCV control cells but not in cells expressing Stat3D (Figure 14).
To be certain that the effects we were witnessing in mouse cells also occurred in
human cells, we examined the role of Stat3 in the hypoxic induction of HIF-1α in A2058
human melanoma cells. Stat3 is constitutively activated in these cells due to activity of cSrc (158). When A2058 cells were treated with inhibitors of c-Src, Stat3 activation as
well as HIF-1α induction by hypoxia was significantly reduced (Figure 15). To determine
the effects of silencing Stat3 on HIF-1α induction by hypoxia, A2058 cells stably
expressing Stat3 siRNA were created. When these cells were exposed to either 1% O2 or
B
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CoCl2, HIF-1α induction was significantly limited in Stat3 siRNA but not in control cells
B

B
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FIGURE 14. Stat3 is required for hypoxia induced HIF-1α expression in v-Src
transformed Fibroblasts. BALB/c fibroblasts transformed with v-Src were stably
transduced with empty vector MSCV or Stat3D. Cells were cultured for 20h in serum
free media followed by treatment with the hypoxia mimic CoCL2 (125uM) for 6h. (A)
Nuclear extracts (30ug) were analyzed by Western blotting using the indicated
antibodies. SP-1 and β-actin are used to verify equal loading. (B) Stat3 DNA binding was
determined by EMSA using nuclear extracts (8ug).
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FIGURE 15. Treatment with Src inhibitors prevents HIF-1α by hypoxia. A2058
human melanoma cells were seeded at 1.5 x 106 approximately 24 h prior to treatment
with inhibitors. Cell were treated with Src inhibitors in serum free media for
approximately 18 hours, and then incubated under hypoxia in the presence of inhibitors
for 6 hours. Nuclear extracts (30µg) were analyzed by Western blot using the indicated
antibodies.
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FIGURE 16. Stat3 is required for HIF-1α induction by hypoxia in A2058 melanoma
cells. A2058 cells were stably-transfected with empty pSilencer or pSilencer-Stat3
siRNA. Cells were serum starved for 20h followed by culture under conditions of 21%
O2, 1% O2, or treatment with CoCL2 (150uM). Nuclear extracts (30µg) (Top panel) and
whole cell extracts (30µg) (middle panel) were analyzed by Western blotting using the
indicated antibodies.
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(Figure 16). These data clearly indicate that inhibition of Stat3 signaling prevents HIF-1α
expression by Src as well as its induction by hypoxia.Because of the possibility that Stat3
was directly acting on the HIF-1α promoter, levels of HIF-1α mRNA were examined. In
BALB/c-3T3-v-Src cells, HIF-1α mRNA expression was significantly decreased
following transduction with Stat3D (data not shown). However, examination of HIF-1α
mRNA in A2058 human melanoma showed no difference in RNA expression, or possibly
even increased levels in cells in which Stat3 had been silenced (Figure 17). Because it has
been reported that Src may regulate HIF-1α at the level of mRNA in non-human cells but
not in human cells (109), and our findings seemed to corroborate these reports, we did
not investigate these results further. We conclude that at least in A2058 human melanoma
cells, regulation of HIF-1α protein by Stat3 cannot be accounted for by changes in
mRNA.

Stat3 is required for the hypoxic induction of VEGF and MMP-2

The evidence that Stat3 is an important regulator of angiogenesis is continuously
increasing. Several reports have indicated that Stat3 is required for VEGF production,
both at the basal level in various cancer cells (159, 214) as well as for its induction by IL6 (215). Furthermore, recent reports have indicated that Stat3 regulates MMP-2 (223) and
MMP-9 (41), both of which are important for the reorganization of the extracellular
matrix during angiogenesis (149). The metalloproteinase genes are potentially regulated
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FIGURE 17. HIF-1α mRNA in A2058 melanoma treated with CoCl2. A2058 cells
were stably-transfected with empty pSilencer or pSilencer-Stat3 siRNA. Cells were
serum starved for 20h followed by treatment with CoCL2 (125uM) for the indicated
times. Total RNA (15ug) was isolated and analyzed by Northern blotting using a HIF-1α
cDNA probe. A photograph of the ethidium bromide-stained gel verifies equal loading as
demonstrated by the 18S and 28S rRNA bands.
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FIGURE 18. Stat3 is required for VEGF induction by CoCl2 in A2058 melanoma.
A2058 cells stably expressing Stat3 siRNA were exposed to CoCl2 for 48 hours in serum
free media. Whole cell extracts (100ug) were analyzed by Western blotting using the
indicated antibodies.
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by HIF-1α, as they have been shown to be inducible by hypoxia (128). However, it is not
known if Stat3 is required for the hypoxic induction of these genes.
To examine Stat3 regulation of VEGF in response to hypoxia, A2058 cells stably
transfected with Stat3 siRNA were utilized. These cells were treated with the hypoxia
mimic CoCl2 for 48h prior to harvest of whole cell extracts and western blot analysis
B

B

(Figure 18). The long timepoint was utilized in order to obtain maximum VEGF
induction. VEGF was induced significantly in control cells, but not in cells expressing
Stat3 siRNA. These results not only reinforce the importance of Stat3 in VEGF
production, but also for VEGF induction by hypoxia.
BALB/c-3T3 fibroblasts transformed with v-Src were used to study the role of
Stat3 in the hypoxic regulation of MMP-2. These cells were treated with 0.1% O2 or
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CoCl2 for 24 h followed western blot analysis of whole cell extracts (Figure 19). It can be
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seen that both hypoxia and the hypoxia mimic resulted in induction of MMP-2 in MSCV
control cells. However, in cells stably transduced with the dominant negative Stat3D,
MMP-2 induction was prevented. Although it has been reported that Stat3 is necessary
for MMP-2 expression, the requirement for its induction by hypoxia had not been
demonstrated.

Stat3 is activated by hypoxia

Hypoxia results in increased expression of genes important for angiogenesis, and
this increase in gene transcription is dependent on the activation of a limited set of
transcription factors. The best documented transcription factor to be activated by hypoxia
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FIGURE 19. Stat3 is required for MMP-2 induction by hypoxia in Fibroblasts
transformed with v-Src. BALB/c-3T3 fibroblasts transformed with v-Src were
transduced with dominant negative Stat3D or control MSCV. Cells were exposed to 0.1%
O2 or CoCl2 for 24h hours in serum free media. Whole cell extracts (100ug) were
analyzed by Western blotting using the indicated antibodies.
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FIGURE 20. Stat3 is activated in human cancer cells exposed to hypoxia. DU145
cells (1.5 x 106) were incubated under 21% or 1% O2 in serum free media. Nuclear
extracts (30ug) were analyzed by Western blotting using the indicated antibodies. Stat3
DNA binding was determined by EMSA using nuclear extracts (8ug) (bottom panel).
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is HIF-1. Very recently, there was a report of increased Stat3 phosphorylation following
treatment with CoCl2 in a pancreatic and a prostate cancer cell line (82). Since it is known
B
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that Stat3 directly regulates the VEGF promoter as well as other hypoxia inducible genes,
we wanted to determine if Stat3 was activated by hypoxia.
To examine Stat3 activation by hypoxia, DU145 prostate cancer cells were
exposed to 1% O2 for 24 hours, then nuclear extracts were collected and EMSA was
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performed (Figure 20). A significant increase in Stat3 DNA binding was observed. To
understand this activation in more detail, we wanted to determine the time course of Stat3
activation. Because we could not be certain that O2 concentrations were equal between
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multiple chambers, the hypoxia mimic CoCl2 was utilized instead. When BALB/c-3T3
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fibroblasts were treated with CoCl2 for various time points, significant Stat3 activation
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was seen as soon as 1 hour (Figure 21). Next we examined the time course of Stat3
activation in DU145 human prostate cancer cells. Increased Stat3 activation was seen as
early as 6h, and was highest at the 24h timepoint (Figure 22). At 48h there was loss of
Stat3 activation, however many cells had died or appeared apoptotic. Because HIF-1 is
the main transcription factor to be activated by hypoxia and to facilitate the cellular
response, we wanted to know if Stat3 activation coincided with or followed HIF-1α
induction. HIF-1α levels accumulate rapidly and are already visible at the earliest
timepoint of 30 minutes, indicating that HIF-1α accumulation precedes Stat3 activation
(Figure 22). Since both HIF-1 and Stat3 are transcriptional activators of VEGF, we next
examined the time course of VEGF production. VEGF accumulation correlated closely
with Stat3 activation, peaking at 24h and diminishing at 48h. Conversely, HIF-1α levels
were still elevated at 48h despite massive cell death and diminishing VEGF production.
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FIGURE 21. Time course of Stat3 activation in BALB/c fibroblasts treated with
hypoxia mimic. BALB/c fibroblasts (1.5 x 106) were treated with CoCL2 (125uM) for
the indicated times. Stat3 DNA binding was determined by EMSA using nuclear extracts
(8ug). NIH3T3 fibroblasts expressing EGFR were stimulated with EGF and used as a
marker for Stat3 and Stat1 dimers bound to labeled hSIE probe.
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FIGURE 22. Hypoxia mimic activates Stat3 in DU145 human prostate cancer.
DU145 cells (1.5 x 106) were treated with CoCL2 (150uM) for the indicated times in
serum-free media. Nuclear extracts (30µg) (Top panel) and whole cell extracts (100µg)
(middle panel) were analyzed by Western blotting using the indicated antibodies. HIF-1β
and β-actin are used to verify equal loading. Stat3 DNA binding was determined by
EMSA using nuclear extracts (8ug) (bottom panel). NIH3T3 fibroblasts expressing
EGFR were stimulated with EGF and used as a marker for Stat3 and Stat1 dimers bound
to labeled hSIE probe.
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From these data it is apparent that Stat3 is activated by hypoxia, and this activation
follows and may result from HIF-1α accumulation.
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DISCUSSION

The data in this dissertation confirms and expands the role of Stat3 in
angiogenesis. It is shown for the first time that Stat3 is required for HIF-1α expression
resulting from a variety of growth signals in multiple cell lines. In addition, it is
demonstrated that Stat3 is required for the hypoxic induction of HIF-1α and several
hypoxia inducible genes. Furthermore, activation of Stat3 by hypoxia suggests
importance in the cellular response to hypoxia. Overall, these data firmly establish Stat3
as an extremely important regulator of angiogenesis, through the combined regulation of
both VEGF and HIF-1α.

Stat3 is required for HIF-1α induction by growth/oncogenic signals

It is demonstrated here for the first time that stimulation with IL-6 results in
increased expression of HIF-1α. MCF-7 breast cancer cells were treated with IL-6 for six
hours in serum free media, followed by western blot analysis of nuclear extracts.
Although HIF-1α induction by IL-6 is modest when compared to its induction by
hypoxia, it is significant when compared to that seen by other well documented growth
signals (133) Elevated HIF-1α levels following treatment with IL-6 did not result from
increased transcription as verified by Northern blotting. These data show that IL-6 can be
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added to the long list of cytokines and growth signals capable of increasing HIF-1α
expression during normoxia.
Since the majority of reports indicate that increased production of HIF-1α by
growth signals results from an elevated rate of protein synthesis, we wanted to determine
if this was also true for IL-6. To achieve this, cyclohexamide was added to MCF-7 cells
for various times following treatment with IL-6 for 6 hours. If increased HIF-1α
expression was due to cessation of degradation, the addition of cyclohexamide would
have no effect as protein levels would remain high over time. If the effect of IL-6 was to
increase the rate of protein synthesis, it would be counteracted by the addition of
cyclohexamide and HIF-1α levels would quickly return to that of baseline. Since HIF-1α
levels returned to that of cells not treated with IL-6 within one hour, it was concluded that
the effect of IL-6 on HIF-1α results from an increased rate of protein synthesis.
Since Stat3 is an important effector of IL-6 signaling, we wanted to determine if it
was required for induction of HIF-1α. To achieve this, MCF-7 cells were stably
transfected with Stat3 siRNA, and western blot was performed following stimulation with
IL-6. There was limited induction of HIF-1α in response to IL-6 in cells expressing Stat3
siRNA when compared to control cells. This effect seemed to be applicable to HIF-1α
induction by a variety of growth signals, as induction of HIF-1α by heregulin was also
prevented in MCF-7 cells expressing Stat3 siRNA. Furthermore, HIF-1α induction by
EGF was prevented in DU145 cells treated with Stat3 antisense oligonucleotide. These
findings demonstrate that Stat3 is required for HIF-1α induction by a variety of growth
signals.
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In addition to a requirement for Stat3 in the induction of HIF-1α by growth
signals, we observed loss of basal level expression of HIF-1α when Stat3 was silenced.
Both of these cell lines, MCF-7 breast cancer and DU-145 prostate cancer cells, have low
but detectable basal levels of HIF-1α expression during normoxia. Although Stat3
activation is weak when cultured in serum free media, silencing Stat3 clearly affected
basal level HIF-1α expression. As constitutive HIF-1α expression often occurs in various
cancers during normoxia, Stat3 is also required for this constitutive expression at least in
these cell lines.
It is well established that increased expression of HIF-1α occurs via activation of
the PI3K/AKT pathway. Since it is known that the PI3K/AKT pathway is activated in
response to IL-6 (88), the effects of treatment with IL-6 on HIF-1α induction were not
entirely surprising. Because we were aware of the work of Dr. Chen’s research, we knew
that there was a possible role for Stat3 in the regulation of Akt1 at the transcriptional
level. To verify that this was occurring in our system, protein levels of Akt1 were
determined following silencing of Stat3 in MCF-7 cells. As was expected, total levels of
Akt1 were reduced in Stat3 siRNA cells relative to the control. In addition,
phosphorylated levels of Akt1 and Akt2 were also abolished. In accordance with
published data demonstrating a requirement for Akt in HIF-1α expression, we conclude
that the likely mechanism for Stat3 mediated IL-6 induction of HIF-1α is through
regulation of Akt.
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Stat3 is required for VEGF induction by growth/oncogenic signals

In addition to its effects on HIF-1α, it is shown here that blocking Stat3 signaling
prevents induction of VEGF by multiple growth signals. It has previously been
demonstrated that Stat3 is required for constitutive VEGF expression in several cancer
cell lines, and for expression resulting from transformation with the v-Src oncogene (159,
214). Furthermore, it has been shown that Stat3 is required for VEGF induction by IL-6
(215). We elaborate on these findings by presenting data showing that Stat3 is essential
for VEGF induction by heregulin and EGF. Furthermore, Stat3 is necessary for basal
level VEGF production in MCF-7 breast cancer cells. These results firmly establish the
requirement for Stat3 in expression of VEGF in multiple cell lines, both at the basal level
and for its induction by various growth factors and soluble signals.
It has been reported that inhibition of Stat3 but not PI3K/Akt prevents the
induction of VEGF by IL-6 (215). Since the only known mechanism of Akt regulation of
VEGF is through HIF-1, this finding emphasizes the importance of Stat3 as a direct
transcriptional regulator of VEGF. Although it is well documented that HIF-1 is an
important regulator of the VEGF gene, Stat3 is probably more important at least for some
inducers.
Because several reports have shown that Stat3 regulates VEGF production by
directly binding to its promoter (159, 214), it is likely that the effects we are witnessing
on VEGF production are both direct and indirect. First, by blocking Stat3 signaling, we
are directly downregulating VEGF production by decreasing availability of one of its
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transcriptional activators. Second, we are decreasing availability of another critical
transcriptional activator, HIF-1α. This idea of Stat3 as a dual regulator is consistent with
the dramatic decreases in VEGF levels that we are witnessing, as levels of VEGF are
entirely eliminated when Stat3 is blocked. However, in many of these same experiments
HIF-1α induction is only partially prevented. So it is likely that the dramatic decreases in
VEGF observed following silencing Stat3 results from the combined effect of loss of
Stat3 as well as HIF-1α.

Stat3 is required for HIF-1α induction by hypoxia

Induction of HIF-1α by hypoxia has been extensively studied and is well
characterized. Under conditions of normal oxygen, HIF-1α is rapidly and continuously
degraded. When O2 becomes limiting, HIF-1α is stabilized and protein rapidly
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accumulates. This process occurs independently from the increased rate of synthesis that
occurs due to PI3K/AKT activation. Both increased synthesis and decreased degradation
can coordinately increase HIF-1α levels in an additive manner. However, there are
conflicting reports concerning whether or not the PI3K/AKT pathway is required for the
hypoxic induction of HIF-1α. Several groups have shown that inhibition of PI3K with
chemical inhibitors or dominant negative forms could prevent HIF induction by hypoxia
(27, 91, 236). Furthermore, it has been reported that overexpression of PTEN, a negative
regulator of PI3K, prevented the hypoxic induction of HIF-1α (238). However, other
reports indicate that HIF-1α induction by hypoxia is not prevented by genetic inhibition
of PI3K/AKT pathway or by treatment with chemical inhibitors (2, 6, 8, 113).
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Importantly, chemical inhibition of PI3K prevented AKT activation while simultaneously
having no effect on the hypoxic induction of HIF-1α (2, 8). These reports make a
convincing argument that AKT is not required for the induction of HIF-1α by hypoxia.
Since we had observed loss of AKT expression following silencing of Stat3, we
concluded that this accounts for decreased HIF-1α expression following stimulation with
IL-6 or growth signals. However, decreased AKT expression should not prevent HIF-1α
induction by hypoxia. Therefore, if silencing Stat3 also prevented HIF-1α induction by
hypoxia, it is likely that some other mechanism is responsible.
To determine if Stat3 is necessary for HIF-1α induction by hypoxia, 3T3
fibroblasts expressing v-Src were transduced with Stat3D. Following treatment with
CoCl2, HIF-1α induction was prevented in cells expressing Stat3D. We next examined
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HIF-1α induction in A2058 human melanoma cells, which have constitutively activated
c-Src (158). When these cells were treated with Src inhibitors, the hypoxic induction of
HIF-1α was prevented. These findings verify published reports indicating that c-Src is
necessary for HIF-1α induction by hypoxia (82). When these same cells were stably
transfected with Stat3 siRNA, HIF-1α induction by hypoxia was prevented. These data
demonstrate that Stat3 is required for HIF-1α induction by hypoxia in both 3T3
fibroblasts expressing v-Src and A2058 human melanoma.
These findings suggest that the effect of Stat3 on HIF-1α is not entirely due to the
ability of Stat3 to regulate AKT expression. This reasoning is underscored by the fact that
we continuously witness decreased basal level expression of HIF-1α when Stat3 is
silenced or blocked with Stat3D. Although Stat3 clearly regulates AKT expression and
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this will affect HIF-1α induction by growth/oncogenic signaling pathways, it is likely
that Stat3 influences HIF-1α by some additional mechanism. Two other potential ways
that Stat3 could regulate HIF-1α expression are via transcriptional control and/or control
over its rate of degradation.
To determine if blocking Stat3 signaling affected levels of HIF-1α mRNA,
Northern blotting was performed. In Balb/c-3T3 fibroblasts transformed with v-Src, there
was decreased levels of HIF-1α RNA when these cell were transduced with Stat3D. This
was not entirely surprising, as it had been reported that v-Src transformation resulted in
increased HIF-1α mRNA levels in rat fibroblasts (109). However, in human cells
transfected with activated c-Src there was elevated HIF-1α protein without a concurrent
increase in mRNA (116). When we examined mRNA levels in A2058 human melanoma
cells, silencing Stat3 did not reduce HIF-1α mRNA. Surprisingly, there appeared to be
slightly elevated levels of RNA in Stat3 siRNA cells. Regardless, RNA could not account
for the effects we were witnessing at the protein level in the human cells. Since these
results seemed to comply with previously published findings, we concluded that mRNA
regulation plays no role in Stat3 control of HIF-1α expression, at least in A2058 human
melanoma.
Since we had eliminated transcriptional regulation as a potential mechanism in
A2058 cells, we investigated the possibility that Stat3 regulates HIF-1α stability.
Previous work in Dr. Yu’s lab demonstrated reciprocal regulation of p53 by Stat3.
Because it has been shown that silencing p53 results in stabilization of HIF-1α during
normoxia (167), we investigated this as another potential mechanism for Stat3 regulation
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of HIF-1α. When Stat3 was silenced in A2058 melanoma cells, we observed increased
p53 expression and decreased HIF-1α expression during hypoxia. If the effects of Stat3
on HIF-1α were through p53, we theorized that loss of p53 would abolish Stat3 control
of HIF-1α. However, when we silenced p53 in these cells we observed no change in HIF1α levels, either during normoxia or hypoxia. Therefore, p53 was eliminated as a
potential mechanism, at least in this cell line.
Another potential mechanism for Stat3 regulation of HIF-1α degradation
concerns PHD enzymes and prolyl hydroxylation. It has been reported that in cells
transformed with v-Src and RasV12 oncogenes, there was HIF-1α stabilization during
normoxia and loss of hydroxylated proline residue 564 (26). Since loss of prolyl
hydroxylation should theoretically only occur as oxygen levels decrease, the authors
attributed this to oncogenic downregulation of prolyl hydroxylase enzyme or activity.
They also reported that transfection with a constitutively activated version of AKT
resulted in increased HIF-1α expression without loss of hydroxylation, suggesting that
this second mode of oncogenic regulation of HIF-1α occurs independently of AKT. This
idea of an additional mode of oncogenic regulation of HIF-1α is consistent with our
findings, and it seems likely that Stat3 influences HIF-1α levels both through increased
synthesis via PI3K/AKT and by influencing hypoxia regulated degradation. Because
PHD-2 is the enzyme primarily responsible for hydroxylation of HIF-1α prolyl residues
(4), and results in stabilization HIF-1α when silenced, we wanted to determine if it was
regulated by Stat3. The idea is that silencing Stat3 will result in elevated levels of PHD-2,
which in turn will increase HIF-1α degradation. However, we observed no change in
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levels of PHD-2 when Stat3 was silenced in A2058 cells or when fibroblasts were
transduced with Stat3D. The authors of the original study made use of an antibody
specific for the hydroxylated form of HIF-1α, to which we did not have access. Through
the use of this antibody it would be possible to further study the role of prolyl
hydroxylation in Stat3 regulation of HIF-1α.
The requirement for Stat3 in the hypoxic induction of HIF-1α we observed
occurred in cell lines expressing v-Src or those that had activated c-Src. However, we did
not examine the hypoxic regulation of HIF-1α in other cell lines. It has recently been
reported that both Stat3 and HIF-1 are required for VEGF expression in response to Src
activation or hypoxia (82). They suggest that Src, Stat3, and HIF-1 cooperatively induce
VEGF expression in response to hypoxia. These findings are not entirely surprising,
because Src is required for the hypoxic expression of both VEGF (155) and HIF-1α (82).
Furthermore, Src is activated by hypoxia (47, 156) and transfection with v-Src or
activated c-Src increases HIF-1α levels (109, 116) as well as activating Stat3(228). It is
possible that Src is a key player in the hypoxic response and cooperatively utilizes HIF1α and Stat3 to facilitate that response.

Stat3 is required for induction of several hypoxia inducible genes

To further study the role of Stat3 as a facilitator of angiogenesis, we wanted to
determine if Stat3 was required for the hypoxic induction of several hypoxia inducible
genes. It has been reported that Stat3 is required for oncogenic expression of VEGF (159,
214, 215). Here we demonstrate that in addition to preventing its induction by oncogenes
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and growth signals, silencing Stat3 prevents the hypoxic induction of VEGF. This finding
verifies a recently published report showing that Stat3 is required for the hypoxic
induction of VEGF (82). In addition, it has been shown that Stat3 is required for
production of the matrix metalloproteinase enzymes MMP-2 and MMP-9 (41, 223).
These enzymes are essential for the degradation of the extracellular matrix as occurs
during angiogenesis, and are inducible by hypoxia (128). We report here that in BALB/c3T3 fibroblasts transformed with the v-Src oncogene, expression of MMP-2 is
significantly reduced in cells expressing the dominant negative Stat3D. Furthermore,
there is induction of MMP-2 by hypoxia in control MSCV cells, but this induction is
abolished in cells expressing Stat3D. These data demonstrate that Stat3 is required for the
hypoxic induction VEGF and MMP-2. Since it has been demonstrated that Stat3 controls
both of these genes at the transcriptional level, it is likely that they are directly under its
control. However, they are also under transcriptional control by HIF-1α. Since we report
here that Stat3 is necessary for HIF-1α expression, blocking Stat3 likely results in their
inhibition both directly and indirectly through HIF-1α.

Stat3 is activated by hypoxia

The manner by which HIF-1α is activated by hypoxia is beginning to be well
understood. Briefly, HIF-1α is hydroxylated by the PHD enzymes only in the presence of
oxygen. VHL binds to hydroxylated HIF-1α and facilitates its degradation. As O2 levels
B

B

decrease, HIF-1α is no longer hydroxylated, interaction with VHL is impeded and
degradation ceases. Although HIF-1α activation by hypoxia is well characterized,
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activation of growth signaling pathways by hypoxia is not clearly understood. It has been
reported that activation of the PI3K/AKT pathway, as measured by AKT
phosphorylation, occurs in some cell lines (2, 3, 8, 29, 238). However, hypoxic activation
of AKT is not universal as with HIF-1α, and was not observed in other cell lines
including breast cancers and prostate cancers (2, 13, 236). Furthermore, it has been
reported that PI3K/AKT activation, when it did occur, followed HIF-1α activation (2).
Concerning Stat3 activation by hypoxia, it has recently been reported that there
are increased levels of phosphorylated Stat3 following treatment with CoCl2. Previously,
B

B

it had been shown that cardiotrophin-1 activates Stat3 via a gp130-dependent signaling
pathway in response to hypoxia (92). In addition it has been reported that Stat5 is
activated by hypoxia (114). Furthermore, it has been shown that c-Src is activated by
hypoxia (47, 156), and this could account for increased Stat3 activation by hypoxia.
Because Stat3 is required for expression of HIF-1α and several hypoxia inducible genes,
we decided to investigate its activation by hypoxia in more detail.
In DU145 prostate cancer cells, there was significant Stat3 activation following
24h incubation in hypoxia. Because we could not measure the exact oxygen
concentration in the hypoxia chamber, and were not certain that levels were equal
between chambers, we could not accurately determine the time course of Stat3 activation
using hypoxia. As an alternative, the hypoxia mimic CoCl2 was employed. In BALB/c
B

B

fibroblasts, there was a significant activation of Stat3 within one hour which increased up
to 4 h. Longer time points were not examined in these cells. In DU145 human prostate
cancer cells, there was detectable activation of Stat3 as early as 2h, and this peaked at
24h. Stat3 activation was significantly diminished at 48h, coinciding with massive cell
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death. In addition to detection of Stat3 activation by EMSA, both nuclear extracts and
whole cell extracts were analyzed by western blot to determine levels of HIF-1α and
VEGF. In contrast to Stat3 activation, HIF-1α accumulation was extremely rapid with
detectable protein at the earliest time point of 30 minutes. HIF-1α levels increased
steadily up to the 24h timepoint. At 48h when Stat3 signaling had diminished and cells
were beginning to die, HIF-1α levels remained high. Expression of VEGF closely
paralleled that of Stat3 activation, with detectable levels at 6h that peaked at 24h and
diminished at 48h. These data emphasize the close relationship between Stat3 activation
and VEGF expression. Although we observed hypoxic activation of Stat3 in DU145 cells,
this was not observed in A2058 human melanoma cells. Therefore, similar to reports
concerning AKT activation, it seems likely that Stat3 activation by hypoxia is cell type
specific. Furthermore, Stat3 activation occurred following HIF-1α induction as reported
for the hypoxic activation of AKT.
The only known transcription factor reported to increase VEGF production in
response to hypoxia is HIF-1α. However, it has recently been reported that hypoxic
induction of VEGF occurred in the absence of HIF-1α expression (153). Furthermore, a
tumor cell line expressing constitutively activated AKT but lacking HIF-1 was able to
form large and well vascularized tumors (5, 142). These reports suggest that other
transcription factors are able to stimulate VEGF production in response to hypoxia
independently of HIF-1α. Because Stat3 is also a transcriptional activator of VEGF, and
we observed Stat3 activation following incubation in hypoxia in both BALB/c fibroblasts
and human prostate cancer, it should be determined if Stat3 can facilitate the hypoxic
induction of VEGF independently of HIF-1α. Although we had found that Stat3
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activation occurred following induction of HIF-1α, it does not necessarily mean that
Stat3 activation is dependent on HIF-1α. It is possible that Stat3 activation occurs in the
absence of HIF-1α but just not as rapidly. Additional experiments should be performed to
determine if Stat3 activation and increased VEGF production occur in response to
hypoxia following silencing of HIF-1α. If both Stat3 activation and VEGF production
occur independently of HIF-1α, further studies may be warranted. Reporter systems
driven by the VEGF promoter containing mutated HIF-1 and Stat3 binding sites could be
constructed to determine the relative importance of each transcription factor for the
hypoxic response.

Stat3 as an antiangiogenic target

The data in this dissertation, along with recently published reports, position Stat3
as an important target for antiangiogenic therapy. It has been demonstrated repeatedly
that Stat3 is a direct regulator of the VEGF gene, and is required for VEGF production in
response to a variety of stimuli in different cell types. Furthermore, it has been shown
that Stat3 is required for other important facilitators of angiogenesis such as MMP-2 and
MMP-9. Importantly, it is demonstrated here that Stat3 is essential for expression of HIF1α, the best documented transcriptional activator of VEGF and a wide variety of other
angiogenic and invasive genes. Therefore, blocking Stat3 not only directly prevents
production of multiple factors essential for angiogenesis, but also blocks production of
the best documented angiogenesis transcription factor. These results strongly suggest that
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targeting Stat3 could completely abrogate angiogenesis by simultaneously eliminating the
activity of its two most important transcription factors.
For successful antiangiogenic therapy to succeed, it is necessary to have
extremely potent angiogenesis inhibitors (12). The classes of angiogenesis inhibitors have
been divided into ‘direct’ and ‘indirect’ based on which cells they target (118). Direct
inhibitors are those that inhibit growth of vascular endothelial cells by targeting them
directly. One advantage to the use of direct inhibitors is that endothelial cells are
genetically stable, and therefore less likely to acquire drug resistance (119). Indirect
angiogenesis inhibitors are those that target the cancer cells, generally by blocking
expression of angiogenic proteins. Any inhibitor that could successfully act in a both
direct and indirect manner would have greater potency and better likelihood for success.
In addition to the requirement of Stat3 for angiogenic factor production by tumor cells,
several reports have indicated that Stat3 is essential for vascular endothelial cell growth,
migration, and microvascular tube formation. Stat3 is activated by and necessary for
signaling by both the bFGF receptor and VEGFR2 (7, 42, 176). Furthermore, Stat3 is
required for endothelial cell migration and microvascular tube formation (225).
Therefore, any drug targeting Stat3 would be functioning simultaneously as both a
primary and secondary angiogenesis inhibitor, and would likely have greater potency
because of this.
Although antiangiogenic therapy has demonstrated efficacy in some clinical trials,
many have had limited success (12, 54, 115, 226). The inhibitors used in these trials
targeted only individual inducers of endothelial cell growth, such as VEGF, EGFR,
VEGFR, and HER-2/neu (118). Since there are a variety of factors involved with
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promoting angiogenesis, targeting only one of these may not be effective. However, the
activity of many of these pathways is dependent on a relatively limited set of
transcription factors. Because of this, selective inactivation of a few TFs could potentially
inactivate a large array of angiogenic factors (39). There is current work investigating the
effect of targeting HIF-1α for anti-angiogenic therapy (180). Since we show here that
Stat3 is necessary for both HIF-1α expression and endothelial cell growth, Stat3 may
prove to be the better transcription factor to target for antiangiogenic therapy.
In summary, there are multple reasons why Stat3 inhibition will likely be an
extremely effective antiangiogenic strategy. Stat3 is required for the production of a
variety of angiogenic factors, in response to both growth/oncogenic signaling and
hypoxia. Furthermore, Stat3 signaling is required for expression of HIF-1α, and therefore
its inhibition could potentially prevent expression of a large array of angiogenic and
invasive factors. Also, any angiogenesis inhibitor capable of preventing endothelial cell
growth in both a direct and indirect manner simultaneously would have a distinct
advantage. Furthermore, it is well documented that Stat3 is an important facilitator of cell
survival and growth, so blocking Stat3 could make both tumor cells and endothelial cells
more prone to apoptosis. Finally, targeting transcription factors will likely prove more
effective because of their role as convergence points for a multitude of angiogenic
factors. For these reasons, drugs that inhibit Stat3 will likely be important therapeutic
tools for antiangiogenic treatments.

80

REFERENCES

1.

Alfranca, A., M. D. Gutierrez, A. Vara, J. Aragones, F. Vidal, and M. O.

Landazuri. 2002. c-Jun and hypoxia-inducible factor 1 functionally cooperate in

hypoxia-induced gene transcription. Mol Cell Biol 22:12-22.

2.

Alvarez-Tejado, M., A. Alfranca, J. Aragones, A. Vara, M. O. Landazuri,

and L. del Peso. 2002. Lack of evidence for the involvement of the

phosphoinositide 3-kinase/Akt pathway in the activation of hypoxia-inducible

factors by low oxygen tension. J Biol Chem 277:13508-17.

3.

Alvarez-Tejado, M., S. Naranjo-Suarez, C. Jimenez, A. C. Carrera, M. O.

Landazuri, and L. del Peso. 2001. Hypoxia induces the activation of the

phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells: protective

role in apoptosis. J Biol Chem 276:22368-74.

81

4.

Appelhoff, R. J., Y. M. Tian, R. R. Raval, H. Turley, A. L. Harris, C. W.

Pugh, P. J. Ratcliffe, and J. M. Gleadle. 2004. Differential function of the

prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-

inducible factor. J Biol Chem 279:38458-65.

5.

Arsham, A. M., D. R. Plas, C. B. Thompson, and M. C. Simon. 2004. Akt and

hypoxia-inducible factor-1 independently enhance tumor growth and

angiogenesis. Cancer Res 64:3500-7.

6.

Arsham, A. M., D. R. Plas, C. B. Thompson, and M. C. Simon. 2002.

Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic

stabilization of HIF-1 alpha nor sufficient for HIF-1-dependent target gene

transcription. J Biol Chem 277:15162-70.

7.

Bartoli, M., D. Platt, T. Lemtalsi, X. Gu, S. E. Brooks, M. B. Marrero, and R.

B. Caldwell. 2003. VEGF differentially activates STAT3 in microvascular

endothelial cells. Faseb J 17:1562-4.

82

8.

Beitner-Johnson, D., R. T. Rust, T. C. Hsieh, and D. E. Millhorn. 2001.

Hypoxia activates Akt and induces phosphorylation of GSK-3 in PC12 cells. Cell

Signal 13:23-7.

9.

Benjamin, L. E., D. Golijanin, A. Itin, D. Pode, and E. Keshet. 1999. Selective

ablation of immature blood vessels in established human tumors follows vascular

endothelial growth factor withdrawal. J Clin Invest 103:159-65.

10.

Bhattacharya, S., C. L. Michels, M. K. Leung, Z. P. Arany, A. L. Kung, and

D. M. Livingston. 1999. Functional role of p35srj, a novel p300/CBP binding

protein, during transactivation by HIF-1. Genes Dev 13:64-75.

11.

Bilton, R. L., and G. W. Booker. 2003. The subtle side to hypoxia inducible

factor (HIFalpha) regulation. Eur J Biochem 270:791-8.

12. Blagosklonny, M. V. 2004. Antiangiogenic therapy and tumor progression. Cancer

Cell 5:13-7.

83

13.

Blancher, C., J. W. Moore, N. Robertson, and A. L. Harris. 2001. Effects of

ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor

(HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and

their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.

Cancer Res 61:7349-55.

14.

Bowman, T., M. A. Broome, D. Sinibaldi, W. Wharton, W. J. Pledger, J. M.

Sedivy, R. Irby, T. Yeatman, S. A. Courtneidge, and R. Jove. 2001. Stat3-

mediated Myc expression is required for Src transformation and PDGF-induced

mitogenesis. Proc Natl Acad Sci U S A 98:7319-24.

15.

Bowman, T., R. Garcia, J. Turkson, and R. Jove. 2000. STATs in oncogenesis.

Oncogene 19:2474-88.

16.

Brizel, D. M., R. K. Dodge, R. W. Clough, and M. W. Dewhirst. 1999.

Oxygenation of head and neck cancer: changes during radiotherapy and impact on

treatment outcome. Radiother Oncol 53:113-7.

17.

Bromberg, J., and J. E. Darnell, Jr. 2000. The role of STATs in transcriptional

control and their impact on cellular function. Oncogene 19:2468-73.
84

18.

Bromberg, J. F., C. M. Horvath, D. Besser, W. W. Lathem, and J. E. Darnell,

Jr. 1998. Stat3 activation is required for cellular transformation by v-src. Mol

Cell Biol 18:2553-8.

19.

Bromberg, J. F., C. M. Horvath, Z. Wen, R. D. Schreiber, and J. E. Darnell,

Jr. 1996. Transcriptionally active Stat1 is required for the antiproliferative effects

of both interferon alpha and interferon gamma. Proc Natl Acad Sci U S A

93:7673-8.

20.

Bromberg, J. F., M. H. Wrzeszczynska, G. Devgan, Y. Zhao, R. G. Pestell, C.

Albanese, and J. E. Darnell, Jr. 1999. Stat3 as an oncogene. Cell 98:295-303.

21.

Bruick, R. K. 2000. Expression of the gene encoding the proapoptotic Nip3

protein is induced by hypoxia. Proc Natl Acad Sci U S A 97:9082-7.

22.

Brusselmans, K., F. Bono, P. Maxwell, Y. Dor, M. Dewerchin, D. Collen, J.

M. Herbert, and P. Carmeliet. 2001. Hypoxia-inducible factor-2alpha (HIF-

2alpha) is involved in the apoptotic response to hypoglycemia but not to hypoxia.

J Biol Chem 276:39192-6.

85

23.

Buettner, R., L. B. Mora, and R. Jove. 2002. Activated STAT signaling in

human tumors provides novel molecular targets for therapeutic intervention. Clin

Cancer Res 8:945-54.

24.

Carmeliet, P., and R. K. Jain. 2000. Angiogenesis in cancer and other diseases.

Nature 407:249-57.

25.

Catlett-Falcone, R., T. H. Landowski, M. M. Oshiro, J. Turkson, A. Levitzki,

R. Savino, G. Ciliberto, L. Moscinski, J. L. Fernandez-Luna, G. Nunez, W. S.

Dalton, and R. Jove. 1999. Constitutive activation of Stat3 signaling confers

resistance to apoptosis in human U266 myeloma cells. Immunity 10:105-15.

26.

Chan, D. A., P. D. Sutphin, N. C. Denko, and A. J. Giaccia. 2002. Role of

prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha.

J Biol Chem 277:40112-7.

27.

Chandel, N. S., D. S. McClintock, C. E. Feliciano, T. M. Wood, J. A.

Melendez, A. M. Rodriguez, and P. T. Schumacker. 2000. Reactive oxygen

species generated at mitochondrial complex III stabilize hypoxia-inducible factor-

1alpha during hypoxia: a mechanism of O2 sensing. J Biol Chem 275:25130-8.
86

28.

Chen, C., N. Pore, A. Behrooz, F. Ismail-Beigi, and A. Maity. 2001.

Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-

ras and hypoxia. J Biol Chem 276:9519-25.

29.

Chen, E. Y., N. M. Mazure, J. A. Cooper, and A. J. Giaccia. 2001. Hypoxia

activates a platelet-derived growth factor receptor/phosphatidylinositol 3-

kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation.

Cancer Res 61:2429-33.

30.

Chung, J., R. E. Bachelder, E. A. Lipscomb, L. M. Shaw, and A. M.

Mercurio. 2002. Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF

translation: a survival mechanism for carcinoma cells. J Cell Biol 158:165-74.

31.

Claffey, K. P., S. C. Shih, A. Mullen, S. Dziennis, J. L. Cusick, K. R. Abrams,

S. W. Lee, and M. Detmar. 1998. Identification of a human VPF/VEGF 3'

untranslated region mediating hypoxia-induced mRNA stability. Mol Biol Cell

9:469-81.

87

32.

Clarke, K., K. Smith, W. J. Gullick, and A. L. Harris. 2001. Mutant epidermal

growth factor receptor enhances induction of vascular endothelial growth factor

by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway.

Br J Cancer 84:1322-9.

33.

Cohen, T., D. Nahari, L. W. Cerem, G. Neufeld, and B. Z. Levi. 1996.

Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol

Chem 271:736-41.

34.

Conrad, P. W., T. L. Freeman, D. Beitner-Johnson, and D. E. Millhorn. 1999.

EPAS1 trans-activation during hypoxia requires p42/p44 MAPK. J Biol Chem

274:33709-13.

35.

Damert, A., E. Ikeda, and W. Risau. 1997. Activator-protein-1 binding

potentiates the hypoxia-induciblefactor-1-mediated hypoxia-induced

transcriptional activation of vascular-endothelial growth factor expression in C6

glioma cells. Biochem J 327 ( Pt 2):419-23.

88

36.

Damert, A., M. Machein, G. Breier, M. Q. Fujita, D. Hanahan, W. Risau, and

K. H. Plate. 1997. Up-regulation of vascular endothelial growth factor expression

in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. Cancer

Res 57:3860-4.

37.

Danial, N. N., A. Pernis, and P. B. Rothman. 1995. Jak-STAT signaling

induced by the v-abl oncogene. Science 269:1875-7.

38.

Dankbar, B., T. Padro, R. Leo, B. Feldmann, M. Kropff, R. M. Mesters, H.

Serve, W. E. Berdel, and J. Kienast. 2000. Vascular endothelial growth factor

and interleukin-6 in paracrine tumor-stromal cell interactions in multiple

myeloma. Blood 95:2630-6.

39.

Darnell, J. E., Jr. 2002. Transcription factors as targets for cancer therapy. Nat

Rev Cancer 2:740-9.

40.

de Vries, C., J. A. Escobedo, H. Ueno, K. Houck, N. Ferrara, and L. T.

Williams. 1992. The fms-like tyrosine kinase, a receptor for vascular endothelial

growth factor. Science 255:989-91.

89

41.

Dechow, T. N., L. Pedranzini, A. Leitch, K. Leslie, W. L. Gerald, I. Linkov,

and J. F. Bromberg. 2004. Requirement of matrix metalloproteinase-9 for the

transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad

Sci U S A 101:10602-7.

42.

Deo, D. D., T. W. Axelrad, E. G. Robert, V. Marcheselli, N. G. Bazan, and J.

D. Hunt. 2002. Phosphorylation of STAT-3 in response to basic fibroblast growth

factor occurs through a mechanism involving platelet-activating factor, JAK-2,

and Src in human umbilical vein endothelial cells. Evidence for a dual kinase

mechanism. J Biol Chem 277:21237-45.

43.

Deroanne, C. F., A. Hajitou, C. M. Calberg-Bacq, B. V. Nusgens, and C. M.

Lapiere. 1997. Angiogenesis by fibroblast growth factor 4 is mediated through an

autocrine up-regulation of vascular endothelial growth factor expression. Cancer

Res 57:5590-7.

44.

Desbaillets, I., A. C. Diserens, N. de Tribolet, M. F. Hamou, and E. G. Van

Meir. 1999. Regulation of interleukin-8 expression by reduced oxygen pressure in

human glioblastoma. Oncogene 18:1447-56.
90

45.

Durand, R. E. 1994. The influence of microenvironmental factors during cancer

therapy. In Vivo 8:691-702.

46.

Ebert, B. L., J. D. Firth, and P. J. Ratcliffe. 1995. Hypoxia and mitochondrial

inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting

sequences. J Biol Chem 270:29083-9.

47.

Ellis, L. M., C. A. Staley, W. Liu, R. Y. Fleming, N. U. Parikh, C. D. Bucana,

and G. E. Gallick. 1998. Down-regulation of vascular endothelial growth factor

in a human colon carcinoma cell line transfected with an antisense expression

vector specific for c-src. J Biol Chem 273:1052-7.

48.

Ema, M., K. Hirota, J. Mimura, H. Abe, J. Yodoi, K. Sogawa, L. Poellinger,

and Y. Fujii-Kuriyama. 1999. Molecular mechanisms of transcription activation

by HLF and HIF1alpha in response to hypoxia: their stabilization and redox

signal-induced interaction with CBP/p300. Embo J 18:1905-14.

91

49.

Ema, M., S. Taya, N. Yokotani, K. Sogawa, Y. Matsuda, and Y. Fujii-

Kuriyama. 1997. A novel bHLH-PAS factor with close sequence similarity to

hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially

involved in lung and vascular development. Proc Natl Acad Sci U S A 94:4273-8.

50.

Esch, F., A. Baird, N. Ling, N. Ueno, F. Hill, L. Denoroy, R. Klepper, D.

Gospodarowicz, P. Bohlen, and R. Guillemin. 1985. Primary structure of

bovine pituitary basic fibroblast growth factor (FGF) and comparison with the

amino-terminal sequence of bovine brain acidic FGF. Proc Natl Acad Sci U S A

82:6507-11.

51.

Feldser, D., F. Agani, N. V. Iyer, B. Pak, G. Ferreira, and G. L. Semenza.

1999. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and

insulin-like growth factor 2. Cancer Res 59:3915-8.

52.

Ferrara, N. 2004. Vascular endothelial growth factor as a target for anticancer

therapy. Oncologist 9 Suppl 1:2-10.

53.

Ferrara, N. 2002. VEGF and the quest for tumour angiogenesis factors. Nat Rev

Cancer 2:795-803.
92

54.

Ferrara, N., H. P. Gerber, and J. LeCouter. 2003. The biology of VEGF and

its receptors. Nat Med 9:669-76.

55.

Ferrara, N., and W. J. Henzel. 1989. Pituitary follicular cells secrete a novel

heparin-binding growth factor specific for vascular endothelial cells. Biochem

Biophys Res Commun 161:851-8.

56.

Finkenzeller, G., A. Sparacio, A. Technau, D. Marme, and G. Siemeister.

1997. Sp1 recognition sites in the proximal promoter of the human vascular

endothelial growth factor gene are essential for platelet-derived growth factor-

induced gene expression. Oncogene 15:669-76.

57.

Firth, J. D., B. L. Ebert, C. W. Pugh, and P. J. Ratcliffe. 1994. Oxygen-

regulated control elements in the phosphoglycerate kinase 1 and lactate

dehydrogenase A genes: similarities with the erythropoietin 3' enhancer. Proc Natl

Acad Sci U S A 91:6496-500.

93

58.

Flamme, I., T. Frohlich, M. von Reutern, A. Kappel, A. Damert, and W.

Risau. 1997. HRF, a putative basic helix-loop-helix-PAS-domain transcription

factor is closely related to hypoxia-inducible factor-1 alpha and developmentally

expressed in blood vessels. Mech Dev 63:51-60.

59.

Folkman, J. 2003. Angiogenesis and apoptosis. Semin Cancer Biol 13:159-67.

60.

Folkman, J. 1971. Tumor angiogenesis: therapeutic implications. N Engl J Med

285:1182-6.

61.

Folkman, J., E. Merler, C. Abernathy, and G. Williams. 1971. Isolation of a

tumor factor responsible or angiogenesis. J Exp Med 133:275-88.

62.

Forsythe, J. A., B. H. Jiang, N. V. Iyer, F. Agani, S. W. Leung, R. D. Koos,

and G. L. Semenza. 1996. Activation of vascular endothelial growth factor gene

transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604-13.

63.

Frank, S., G. Hubner, G. Breier, M. T. Longaker, D. G. Greenhalgh, and S.

Werner. 1995. Regulation of vascular endothelial growth factor expression in

cultured keratinocytes. Implications for normal and impaired wound healing. J

Biol Chem 270:12607-13.
94

64.

Fukuda, R., K. Hirota, F. Fan, Y. D. Jung, L. M. Ellis, and G. L. Semenza.

2002. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated

vascular endothelial growth factor expression, which is dependent on MAP kinase

and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem

277:38205-11.

65.

Funamoto, M., Y. Fujio, K. Kunisada, S. Negoro, E. Tone, T. Osugi, H.

Hirota, M. Izumi, K. Yoshizaki, K. Walsh, T. Kishimoto, and K. Yamauchi-

Takihara. 2000. Signal transducer and activator of transcription 3 is required for

glycoprotein 130-mediated induction of vascular endothelial growth factor in

cardiac myocytes. J Biol Chem 275:10561-6.

66.

Garcia, R., T. L. Bowman, G. Niu, H. Yu, S. Minton, C. A. Muro-Cacho, C.

E. Cox, R. Falcone, R. Fairclough, S. Parsons, A. Laudano, A. Gazit, A.

Levitzki, A. Kraker, and R. Jove. 2001. Constitutive activation of Stat3 by the

Src and JAK tyrosine kinases participates in growth regulation of human breast

carcinoma cells. Oncogene 20:2499-513.

95

67.

Garcia, R., C. L. Yu, A. Hudnall, R. Catlett, K. L. Nelson, T. Smithgall, D. J.

Fujita, S. P. Ethier, and R. Jove. 1997. Constitutive activation of Stat3 in

fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells.

Cell Growth Differ 8:1267-76.

68.

Gerber, H. P., F. Condorelli, J. Park, and N. Ferrara. 1997. Differential

transcriptional regulation of the two vascular endothelial growth factor receptor

genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem

272:23659-67.

69.

Gille, J., R. A. Swerlick, and S. W. Caughman. 1997. Transforming growth

factor-alpha-induced transcriptional activation of the vascular permeability factor

(VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation.

Embo J 16:750-9.

70.

Gingras, A. C., B. Raught, and N. Sonenberg. 2001. Regulation of translation

initiation by FRAP/mTOR. Genes Dev 15:807-26.

96

71.

Gleadle, J. M., B. L. Ebert, J. D. Firth, and P. J. Ratcliffe. 1995. Regulation of

angiogenic growth factor expression by hypoxia, transition metals, and chelating

agents. Am J Physiol 268:C1362-8.

72.

Goad, D. L., J. Rubin, H. Wang, A. H. Tashjian, Jr., and C. Patterson. 1996.

Enhanced expression of vascular endothelial growth factor in human SaOS-2

osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor

I. Endocrinology 137:2262-8.

73.

Goldberg, M. A., and T. J. Schneider. 1994. Similarities between the oxygen-

sensing mechanisms regulating the expression of vascular endothelial growth

factor and erythropoietin. J Biol Chem 269:4355-9.

74.

Gorlach, A., I. Diebold, V. B. Schini-Kerth, U. Berchner-Pfannschmidt, U.

Roth, R. P. Brandes, T. Kietzmann, and R. Busse. 2001. Thrombin activates

the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells:

Role of the p22(phox)-containing NADPH oxidase. Circ Res 89:47-54.

97

75.

Gorski, D. H., H. J. Mauceri, R. M. Salloum, S. Gately, S. Hellman, M. A.

Beckett, V. P. Sukhatme, G. A. Soff, D. W. Kufe, and R. R. Weichselbaum.

1998. Potentiation of the antitumor effect of ionizing radiation by brief

concomitant exposures to angiostatin. Cancer Res 58:5686-9.

76.

Gouilleux-Gruart, V., F. Gouilleux, C. Desaint, J. F. Claisse, J. C. Capiod, J.

Delobel, R. Weber-Nordt, I. Dusanter-Fourt, F. Dreyfus, B. Groner, and L.

Prin. 1996. STAT-related transcription factors are constitutively activated in

peripheral blood cells from acute leukemia patients. Blood 87:1692-7.

77.

Graeber, T. G., C. Osmanian, T. Jacks, D. E. Housman, C. J. Koch, S. W.

Lowe, and A. J. Giaccia. 1996. Hypoxia-mediated selection of cells with

diminished apoptotic potential in solid tumours. Nature 379:88-91.

78.

Graham, C. H., T. E. Fitzpatrick, and K. R. McCrae. 1998. Hypoxia

stimulates urokinase receptor expression through a heme protein-dependent

pathway. Blood 91:3300-7.

98

79.

Grandis, J. R., S. D. Drenning, A. Chakraborty, M. Y. Zhou, Q. Zeng, A. S.

Pitt, and D. J. Tweardy. 1998. Requirement of Stat3 but not Stat1 activation for

epidermal growth factor receptor- mediated cell growth In vitro. J Clin Invest

102:1385-92.

80.

Grandis, J. R., S. D. Drenning, Q. Zeng, S. C. Watkins, M. F. Melhem, S.

Endo, D. E. Johnson, L. Huang, Y. He, and J. D. Kim. 2000. Constitutive

activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis

in vivo. Proc Natl Acad Sci U S A 97:4227-32.

81.

Gray, L. H., A. D. Conger, M. Ebert, S. Hornsey, and O. C. Scott. 1953. The

concentration of oxygen dissolved in tissues at the time of irradiation as a factor

in radiotherapy. Br J Radiol 26:638-48.

82.

Gray, M. J., J. Zhang, L. M. Ellis, G. L. Semenza, D. B. Evans, S. S.

Watowich, and G. E. Gallick. 2005. HIF-1alpha, STAT3, CBP/p300 and Ref-

1/APE are components of a transcriptional complex that regulates Src-dependent

hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas.

Oncogene.
99

83.

Grugel, S., G. Finkenzeller, K. Weindel, B. Barleon, and D. Marme. 1995.

Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth

factor in NIH 3T3 cells. J Biol Chem 270:25915-9.

84.

Grunstein, J., W. G. Roberts, O. Mathieu-Costello, D. Hanahan, and R. S.

Johnson. 1999. Tumor-derived expression of vascular endothelial growth factor

is a critical factor in tumor expansion and vascular function. Cancer Res 59:1592-

8.

85.

Haas-Kogan, D., N. Shalev, M. Wong, G. Mills, G. Yount, and D. Stokoe.

1998. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to

mutation of the tumor suppressor PTEN/MMAC. Curr Biol 8:1195-8.

86.

Hanahan, D., and J. Folkman. 1996. Patterns and emerging mechanisms of the

angiogenic switch during tumorigenesis. Cell 86:353-64.

87.

Harris, A. L. 2002. Hypoxia--a key regulatory factor in tumour growth. Nat Rev

Cancer 2:38-47.

100

88.

Heinrich, P. C., I. Behrmann, S. Haan, H. M. Hermanns, G. Muller-Newen,

and F. Schaper. 2003. Principles of interleukin (IL)-6-type cytokine signalling

and its regulation. Biochem J 374:1-20.

89.

Hellwig-Burgel, T., K. Rutkowski, E. Metzen, J. Fandrey, and W. Jelkmann.

1999. Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding

of hypoxia-inducible factor-1. Blood 94:1561-7.

90.

Hewitson, K. S., L. A. McNeill, M. V. Riordan, Y. M. Tian, A. N. Bullock, R.

W. Welford, J. M. Elkins, N. J. Oldham, S. Bhattacharya, J. M. Gleadle, P. J.

Ratcliffe, C. W. Pugh, and C. J. Schofield. 2002. Hypoxia-inducible factor

(HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is

related to the cupin structural family. J Biol Chem 277:26351-5.

91.

Hirota, K., and G. L. Semenza. 2001. Rac1 activity is required for the activation

of hypoxia-inducible factor 1. J Biol Chem 276:21166-72.

92.

Hishinuma, S., M. Funamoto, Y. Fujio, K. Kunisada, and K. Yamauchi-

Takihara. 1999. Hypoxic stress induces cardiotrophin-1 expression in cardiac

myocytes. Biochem Biophys Res Commun 264:436-40.
101

93.

Hockel, M., and P. Vaupel. 2001. Tumor hypoxia: definitions and current

clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266-76.

94.

Hoekstra, R., F. A. Eskens, and J. Verweij. 2001. Matrix metalloproteinase

inhibitors: current developments and future perspectives. Oncologist 6:415-27.

95.

Hofmann, U. B., J. R. Westphal, E. T. Waas, A. J. Zendman, I. M.

Cornelissen, D. J. Ruiter, and G. N. van Muijen. 1999. Matrix

metalloproteinases in human melanoma cell lines and xenografts: increased

expression of activated matrix metalloproteinase-2 (MMP-2) correlates with

melanoma progression. Br J Cancer 81:774-82.

96.

Houck, K. A., N. Ferrara, J. Winer, G. Cachianes, B. Li, and D. W. Leung.

1991. The vascular endothelial growth factor family: identification of a fourth

molecular species and characterization of alternative splicing of RNA. Mol

Endocrinol 5:1806-14.

102

97.

Huang, J., J. S. Frischer, A. Serur, A. Kadenhe, A. Yokoi, K. W.

McCrudden, T. New, K. O'Toole, S. Zabski, J. S. Rudge, J. Holash, G. D.

Yancopoulos, D. J. Yamashiro, and J. J. Kandel. 2003. Regression of

established tumors and metastases by potent vascular endothelial growth factor

blockade. Proc Natl Acad Sci U S A 100:7785-90.

98.

Huang, L. E., Z. Arany, D. M. Livingston, and H. F. Bunn. 1996. Activation of

hypoxia-inducible transcription factor depends primarily upon redox-sensitive

stabilization of its alpha subunit. J Biol Chem 271:32253-9.

99.

Huang, L. E., and H. F. Bunn. 2003. Hypoxia-inducible factor and its

biomedical relevance. J Biol Chem 278:19575-8.

100.

Hurwitz, H., L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth,

W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe,

B. Rogers, R. Ross, and F. Kabbinavar. 2004. Bevacizumab plus irinotecan,

fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med

350:2335-42.

103

101.

Huss, W. J., R. J. Barrios, and N. M. Greenberg. 2003. SU5416 selectively

impairs angiogenesis to induce prostate cancer-specific apoptosis. Mol Cancer

Ther 2:611-6.

102.

Iliopoulos, O., A. P. Levy, C. Jiang, W. G. Kaelin, Jr., and M. A. Goldberg.

1996. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau

protein. Proc Natl Acad Sci U S A 93:10595-9.

103.

Inoue, M., J. H. Hager, N. Ferrara, H. P. Gerber, and D. Hanahan. 2002.

VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic

beta cell carcinogenesis. Cancer Cell 1:193-202.

104.

Itoh, T., M. Tanioka, H. Yoshida, T. Yoshioka, H. Nishimoto, and S. Itohara.

1998. Reduced angiogenesis and tumor progression in gelatinase A-deficient

mice. Cancer Res 58:1048-51.

105.

Ivan, M., K. Kondo, H. Yang, W. Kim, J. Valiando, M. Ohh, A. Salic, J. M.

Asara, W. S. Lane, and W. G. Kaelin, Jr. 2001. HIFalpha targeted for VHL-

mediated destruction by proline hydroxylation: implications for O2 sensing.

Science 292:464-8.
104

106.

Jaakkola, P., D. R. Mole, Y. M. Tian, M. I. Wilson, J. Gielbert, S. J. Gaskell,

A. Kriegsheim, H. F. Hebestreit, M. Mukherji, C. J. Schofield, P. H.

Maxwell, C. W. Pugh, and P. J. Ratcliffe. 2001. Targeting of HIF-alpha to the

von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Science 292:468-72.

107.

Jain, R. K. 2005. Normalization of tumor vasculature: an emerging concept in

antiangiogenic therapy. Science 307:58-62.

108.

Jeong, J. W., M. K. Bae, M. Y. Ahn, S. H. Kim, T. K. Sohn, M. H. Bae, M. A.

Yoo, E. J. Song, K. J. Lee, and K. W. Kim. 2002. Regulation and

destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111:709-20.

109.

Jiang, B. H., F. Agani, A. Passaniti, and G. L. Semenza. 1997. V-SRC induces

expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes

encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1

in tumor progression. Cancer Res 57:5328-35.

105

110.

Jiang, B. H., J. Z. Zheng, M. Aoki, and P. K. Vogt. 2000. Phosphatidylinositol

3-kinase signaling mediates angiogenesis and expression of vascular endothelial

growth factor in endothelial cells. Proc Natl Acad Sci U S A 97:1749-53.

111.

Jiang, B. H., J. Z. Zheng, S. W. Leung, R. Roe, and G. L. Semenza. 1997.

Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha.

Modulation of transcriptional activity by oxygen tension. J Biol Chem

272:19253-60.

112.

Jimenez, B., O. V. Volpert, S. E. Crawford, M. Febbraio, R. L. Silverstein,

and N. Bouck. 2000. Signals leading to apoptosis-dependent inhibition of

neovascularization by thrombospondin-1. Nat Med 6:41-8.

113.

Jones, A., C. Fujiyama, C. Blanche, J. W. Moore, S. Fuggle, D. Cranston, R.

Bicknell, and A. L. Harris. 2001. Relation of vascular endothelial growth factor

production to expression and regulation of hypoxia-inducible factor-1 alpha and

hypoxia-inducible factor-2 alpha in human bladder tumors and cell lines. Clin

Cancer Res 7:1263-72.

106

114.

Joung, Y. H., J. H. Park, T. Park, C. S. Lee, O. H. Kim, S. K. Ye, U. M.

Yang, K. J. Lee, and Y. M. Yang. 2003. Hypoxia activates signal transducers

and activators of transcription 5 (STAT5) and increases its binding activity to the

GAS element in mammary epithelial cells. Exp Mol Med 35:350-7.

115.

Kabbinavar, F., H. I. Hurwitz, L. Fehrenbacher, N. J. Meropol, W. F.

Novotny, G. Lieberman, S. Griffing, and E. Bergsland. 2003. Phase II,

randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV)

with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol

21:60-5.

116.

Karni, R., Y. Dor, E. Keshet, O. Meyuhas, and A. Levitzki. 2002. Activated

pp60c-Src leads to elevated hypoxia-inducible factor (HIF)-1alpha expression

under normoxia. J Biol Chem 277:42919-25.

117.

Keck, P. J., S. D. Hauser, G. Krivi, K. Sanzo, T. Warren, J. Feder, and D. T.

Connolly. 1989. Vascular permeability factor, an endothelial cell mitogen related

to PDGF. Science 246:1309-12.

107

118.

Kerbel, R., and J. Folkman. 2002. Clinical translation of angiogenesis

inhibitors. Nat Rev Cancer 2:727-39.

119.

Kerbel, R. S. 1997. A cancer therapy resistant to resistance. Nature 390:335-6.

120.

Kieser, A., H. A. Weich, G. Brandner, D. Marme, and W. Kolch. 1994.

Mutant p53 potentiates protein kinase C induction of vascular endothelial growth

factor expression. Oncogene 9:963-9.

121.

Kim, K. J., B. Li, J. Winer, M. Armanini, N. Gillett, H. S. Phillips, and N.

Ferrara. 1993. Inhibition of vascular endothelial growth factor-induced

angiogenesis suppresses tumour growth in vivo. Nature 362:841-4.

122.

Klement, G., S. Baruchel, J. Rak, S. Man, K. Clark, D. J. Hicklin, P. Bohlen,

and R. S. Kerbel. 2000. Continuous low-dose therapy with vinblastine and

VEGF receptor-2 antibody induces sustained tumor regression without overt

toxicity. J Clin Invest 105:R15-24.

108

123.

Klement, G., P. Huang, B. Mayer, S. K. Green, S. Man, P. Bohlen, D. Hicklin,

and R. S. Kerbel. 2002. Differences in therapeutic indexes of combination

metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant

human breast cancer xenografts. Clin Cancer Res 8:221-32.

124.

Knighton, D. R., T. K. Hunt, H. Scheuenstuhl, B. J. Halliday, Z. Werb, and

M. J. Banda. 1983. Oxygen tension regulates the expression of angiogenesis

factor by macrophages. Science 221:1283-5.

125.

Koch, A. E., P. J. Polverini, S. L. Kunkel, L. A. Harlow, L. A. DiPietro, V. M.

Elner, S. G. Elner, and R. M. Strieter. 1992. Interleukin-8 as a macrophage-

derived mediator of angiogenesis. Science 258:1798-801.

126.

Kourembanas, S., R. L. Hannan, and D. V. Faller. 1990. Oxygen tension

regulates the expression of the platelet-derived growth factor-B chain gene in

human endothelial cells. J Clin Invest 86:670-4.

109

127.

Kraker, A. J., B. G. Hartl, A. M. Amar, M. R. Barvian, H. D. Showalter, and

C. W. Moore. 2000. Biochemical and cellular effects of c-Src kinase-selective

pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol 60:885-

98.

128.

Krishnamachary, B., S. Berg-Dixon, B. Kelly, F. Agani, D. Feldser, G.

Ferreira, N. Iyer, J. LaRusch, B. Pak, P. Taghavi, and G. L. Semenza. 2003.

Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1.

Cancer Res 63:1138-43.

129.

Kuwabara, K., S. Ogawa, M. Matsumoto, S. Koga, M. Clauss, D. J. Pinsky,

P. Lyn, J. Leavy, L. Witte, J. Joseph-Silverstein, and et al. 1995. Hypoxia-

mediated induction of acidic/basic fibroblast growth factor and platelet-derived

growth factor in mononuclear phagocytes stimulates growth of hypoxic

endothelial cells. Proc Natl Acad Sci U S A 92:4606-10.

110

130.

Laderoute, K. R., J. M. Calaoagan, C. Gustafson-Brown, A. M. Knapp, G. C.

Li, H. L. Mendonca, H. E. Ryan, Z. Wang, and R. S. Johnson. 2002. The

response of c-jun/AP-1 to chronic hypoxia is hypoxia-inducible factor 1 alpha

dependent. Mol Cell Biol 22:2515-23.

131.

Lando, D., D. J. Peet, J. J. Gorman, D. A. Whelan, M. L. Whitelaw, and R.

K. Bruick. 2002. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the

transcriptional activity of hypoxia-inducible factor. Genes Dev 16:1466-71.

132.

Lando, D., D. J. Peet, D. A. Whelan, J. J. Gorman, and M. L. Whitelaw.

2002. Asparagine hydroxylation of the HIF transactivation domain a hypoxic

switch. Science 295:858-61.

133.

Laughner, E., P. Taghavi, K. Chiles, P. C. Mahon, and G. L. Semenza. 2001.

HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-

1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial

growth factor expression. Mol Cell Biol 21:3995-4004.

111

134.

Lee, C. G., M. Heijn, E. di Tomaso, G. Griffon-Etienne, M. Ancukiewicz, C.

Koike, K. R. Park, N. Ferrara, R. K. Jain, H. D. Suit, and Y. Boucher. 2000.

Anti-Vascular endothelial growth factor treatment augments tumor radiation

response under normoxic or hypoxic conditions. Cancer Res 60:5565-70.

135.

Leung, D. W., G. Cachianes, W. J. Kuang, D. V. Goeddel, and N. Ferrara.

1989. Vascular endothelial growth factor is a secreted angiogenic mitogen.

Science 246:1306-9.

136.

Levy, A. P., N. S. Levy, and M. A. Goldberg. 1996. Post-transcriptional

regulation of vascular endothelial growth factor by hypoxia. J Biol Chem

271:2746-53.

137.

Levy, A. P., N. S. Levy, S. Wegner, and M. A. Goldberg. 1995. Transcriptional

regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol

Chem 270:13333-40.

138.

Levy, D. E., and J. E. Darnell, Jr. 2002. Stats: transcriptional control and

biological impact. Nat Rev Mol Cell Biol 3:651-62.

112

139.

Li, J., M. A. Perrella, J. C. Tsai, S. F. Yet, C. M. Hsieh, M. Yoshizumi, C.

Patterson, W. O. Endege, F. Zhou, and M. E. Lee. 1995. Induction of vascular

endothelial growth factor gene expression by interleukin-1 beta in rat aortic

smooth muscle cells. J Biol Chem 270:308-12.

140.

Liu, Y., S. R. Cox, T. Morita, and S. Kourembanas. 1995. Hypoxia regulates

vascular endothelial growth factor gene expression in endothelial cells.

Identification of a 5' enhancer. Circ Res 77:638-43.

141.

Lok, C. N., and P. Ponka. 1999. Identification of a hypoxia response element in

the transferrin receptor gene. J Biol Chem 274:24147-52.

142.

Maity, A., N. Pore, J. Lee, D. Solomon, and D. M. O'Rourke. 2000. Epidermal

growth factor receptor transcriptionally up-regulates vascular endothelial growth

factor expression in human glioblastoma cells via a pathway involving

phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia. Cancer

Res 60:5879-86.

113

143.

Makino, Y., R. Cao, K. Svensson, G. Bertilsson, M. Asman, H. Tanaka, Y.

Cao, A. Berkenstam, and L. Poellinger. 2001. Inhibitory PAS domain protein is

a negative regulator of hypoxia-inducible gene expression. Nature 414:550-4.

144.

Makino, Y., A. Kanopka, W. J. Wilson, H. Tanaka, and L. Poellinger. 2002.

Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of

the hypoxia-inducible factor-3alpha locus. J Biol Chem 277:32405-8.

145.

Masson, N., and P. J. Ratcliffe. 2003. HIF prolyl and asparaginyl hydroxylases

in the biological response to intracellular O(2) levels. J Cell Sci 116:3041-9.

146.

Mauceri, H. J., N. N. Hanna, M. A. Beckett, D. H. Gorski, M. J. Staba, K. A.

Stellato, K. Bigelow, R. Heimann, S. Gately, M. Dhanabal, G. A. Soff, V. P.

Sukhatme, D. W. Kufe, and R. R. Weichselbaum. 1998. Combined effects of

angiostatin and ionizing radiation in antitumour therapy. Nature 394:287-91.

147.

Maxwell, P. H., M. S. Wiesener, G. W. Chang, S. C. Clifford, E. C. Vaux, M.

E. Cockman, C. C. Wykoff, C. W. Pugh, E. R. Maher, and P. J. Ratcliffe.

1999. The tumour suppressor protein VHL targets hypoxia-inducible factors for

oxygen-dependent proteolysis. Nature 399:271-5.
114

148.

Mazure, N. M., E. Y. Chen, K. R. Laderoute, and A. J. Giaccia. 1997.

Induction of vascular endothelial growth factor by hypoxia is modulated by a

phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells

through a hypoxia inducible factor-1 transcriptional element. Blood 90:3322-31.

149.

McCawley, L. J., and L. M. Matrisian. 2001. Matrix metalloproteinases: they're

not just for matrix anymore! Curr Opin Cell Biol 13:534-40.

150.

Mezquita, P., S. S. Parghi, K. A. Brandvold, and A. Ruddell. 2005. Myc

regulates VEGF production in B cells by stimulating initiation of VEGF mRNA

translation. Oncogene 24:889-901.

151.

Millauer, B., L. K. Shawver, K. H. Plate, W. Risau, and A. Ullrich. 1994.

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant.

Nature 367:576-9.

152.

Minet, E., T. Arnould, G. Michel, I. Roland, D. Mottet, M. Raes, J. Remacle,

and C. Michiels. 2000. ERK activation upon hypoxia: involvement in HIF-1

activation. FEBS Lett 468:53-8.

115

153.

Mizukami, Y., J. Li, X. Zhang, M. A. Zimmer, O. Iliopoulos, and D. C.

Chung. 2004. Hypoxia-inducible factor-1-independent regulation of vascular

endothelial growth factor by hypoxia in colon cancer. Cancer Res 64:1765-72.

154.

Mukhopadhyay, D., L. Tsiokas, and V. P. Sukhatme. 1995. Wild-type p53 and

v-Src exert opposing influences on human vascular endothelial growth factor gene

expression. Cancer Res 55:6161-5.

155.

Mukhopadhyay, D., L. Tsiokas, X. M. Zhou, D. Foster, J. S. Brugge, and V.

P. Sukhatme. 1995. Hypoxic induction of human vascular endothelial growth

factor expression through c-Src activation. Nature 375:577-81.

156.

Namiki, A., E. Brogi, M. Kearney, E. A. Kim, T. Wu, T. Couffinhal, L.

Varticovski, and J. M. Isner. 1995. Hypoxia induces vascular endothelial

growth factor in cultured human endothelial cells. J Biol Chem 270:31189-95.

157.

Ni, Z., W. Lou, E. S. Leman, and A. C. Gao. 2000. Inhibition of constitutively

activated Stat3 signaling pathway suppresses growth of prostate cancer cells.

Cancer Res 60:1225-8.

116

158.

Niu, G., T. Bowman, M. Huang, S. Shivers, D. Reintgen, A. Daud, A. Chang,

A. Kraker, R. Jove, and H. Yu. 2002. Roles of activated Src and Stat3 signaling

in melanoma tumor cell growth. Oncogene 21:7001-10.

159.

Niu, G., K. L. Wright, M. Huang, L. Song, E. Haura, J. Turkson, S. Zhang,

T. Wang, D. Sinibaldi, D. Coppola, R. Heller, L. M. Ellis, J. Karras, J.

Bromberg, D. Pardoll, R. Jove, and H. Yu. 2002. Constitutive Stat3 activity up-

regulates VEGF expression and tumor angiogenesis. Oncogene 21:2000-8.

160.

Pertovaara, L., A. Kaipainen, T. Mustonen, A. Orpana, N. Ferrara, O.

Saksela, and K. Alitalo. 1994. Vascular endothelial growth factor is induced in

response to transforming growth factor-beta in fibroblastic and epithelial cells. J

Biol Chem 269:6271-4.

161.

Petit, A. M., J. Rak, M. C. Hung, P. Rockwell, N. Goldstein, B. Fendly, and

R. S. Kerbel. 1997. Neutralizing antibodies against epidermal growth factor and

ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth

factor production by tumor cells in vitro and in vivo: angiogenic implications for

signal transduction therapy of solid tumors. Am J Pathol 151:1523-30.
117

162.

Plate, K. H., G. Breier, H. A. Weich, and W. Risau. 1992. Vascular endothelial

growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

Nature 359:845-8.

163.

Poon, R. T., S. T. Fan, and J. Wong. 2001. Clinical implications of circulating

angiogenic factors in cancer patients. J Clin Oncol 19:1207-25.

164.

Pugh, C. W., J. F. O'Rourke, M. Nagao, J. M. Gleadle, and P. J. Ratcliffe.

1997. Activation of hypoxia-inducible factor-1; definition of regulatory domains

within the alpha subunit. J Biol Chem 272:11205-14.

165.

Pugh, C. W., and P. J. Ratcliffe. 2003. Regulation of angiogenesis by hypoxia:

role of the HIF system. Nat Med 9:677-84.

166.

Rak, J., Y. Mitsuhashi, L. Bayko, J. Filmus, S. Shirasawa, T. Sasazuki, and

R. S. Kerbel. 1995. Mutant ras oncogenes upregulate VEGF/VPF expression:

implications for induction and inhibition of tumor angiogenesis. Cancer Res

55:4575-80.

118

167.

Ravi, R., B. Mookerjee, Z. M. Bhujwalla, C. H. Sutter, D. Artemov, Q. Zeng,

L. E. Dillehay, A. Madan, G. L. Semenza, and A. Bedi. 2000. Regulation of

tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor

1alpha. Genes Dev 14:34-44.

168.

Repovic, P., C. Y. Fears, C. L. Gladson, and E. N. Benveniste. 2003.

Oncostatin-M induction of vascular endothelial growth factor expression in

astroglioma cells. Oncogene 22:8117-24.

169.

Richard, D. E., E. Berra, E. Gothie, D. Roux, and J. Pouyssegur. 1999.

p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible

factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J

Biol Chem 274:32631-7.

170.

Richard, D. E., E. Berra, and J. Pouyssegur. 2000. Nonhypoxic pathway

mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth

muscle cells. J Biol Chem 275:26765-71.

171.

Rofstad, E. K. 2000. Microenvironment-induced cancer metastasis. Int J Radiat

Biol 76:589-605.
119

172.

Rolfs, A., I. Kvietikova, M. Gassmann, and R. H. Wenger. 1997. Oxygen-

regulated transferrin expression is mediated by hypoxia-inducible factor-1. J Biol

Chem 272:20055-62.

173.

Rupec, R. A., and P. A. Baeuerle. 1995. The genomic response of tumor cells to

hypoxia and reoxygenation. Differential activation of transcription factors AP-1

and NF-kappa B. Eur J Biochem 234:632-40.

174.

Ryuto, M., M. Ono, H. Izumi, S. Yoshida, H. A. Weich, K. Kohno, and M.

Kuwano. 1996. Induction of vascular endothelial growth factor by tumor necrosis

factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem

271:28220-8.

175.

Sargiannidou, I., J. Zhou, and G. P. Tuszynski. 2001. The role of

thrombospondin-1 in tumor progression. Exp Biol Med (Maywood) 226:726-33.

176.

Scheidegger, K. J., J. Du, and P. Delafontaine. 1999. Distinct and common

pathways in the regulation of insulin-like growth factor-1 receptor gene

expression by angiotensin II and basic fibroblast growth factor. J Biol Chem

274:3522-30.
120

177.

Schofield, C. J., and P. J. Ratcliffe. 2004. Oxygen sensing by HIF hydroxylases.

Nat Rev Mol Cell Biol 5:343-54.

178.

Seftor, R. E., E. A. Seftor, W. G. Stetler-Stevenson, and M. J. Hendrix. 1993.

The 72 kDa type IV collagenase is modulated via differential expression of alpha

v beta 3 and alpha 5 beta 1 integrins during human melanoma cell invasion.

Cancer Res 53:3411-5.

179.

Seidel, H. M., L. H. Milocco, P. Lamb, J. E. Darnell, Jr., R. B. Stein, and J.

Rosen. 1995. Spacing of palindromic half sites as a determinant of selective

STAT (signal transducers and activators of transcription) DNA binding and

transcriptional activity. Proc Natl Acad Sci U S A 92:3041-5.

180.

Semenza, G. L. 2003. Targeting HIF-1 for cancer therapy. Nat Rev Cancer

3:721-32.

181.

Semenza, G. L., P. H. Roth, H. M. Fang, and G. L. Wang. 1994.

Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-

inducible factor 1. J Biol Chem 269:23757-63.

121

182.

Semenza, G. L., and G. L. Wang. 1992. A nuclear factor induced by hypoxia via

de novo protein synthesis binds to the human erythropoietin gene enhancer at a

site required for transcriptional activation. Mol Cell Biol 12:5447-54.

183.

Shalaby, F., J. Rossant, T. P. Yamaguchi, M. Gertsenstein, X. F. Wu, M. L.

Breitman, and A. C. Schuh. 1995. Failure of blood-island formation and

vasculogenesis in Flk-1-deficient mice. Nature 376:62-6.

184.

Shi, Q., X. Le, J. L. Abbruzzese, Z. Peng, C. N. Qian, H. Tang, Q. Xiong, B.

Wang, X. C. Li, and K. Xie. 2001. Constitutive Sp1 activity is essential for

differential constitutive expression of vascular endothelial growth factor in human

pancreatic adenocarcinoma. Cancer Res 61:4143-54.

185.

Shi, Q., X. Le, B. Wang, J. L. Abbruzzese, Q. Xiong, Y. He, and K. Xie. 2001.

Regulation of vascular endothelial growth factor expression by acidosis in human

cancer cells. Oncogene 20:3751-6.

186.

Shuai, K., C. M. Horvath, L. H. Huang, S. A. Qureshi, D. Cowburn, and J. E.

Darnell, Jr. 1994. Interferon activation of the transcription factor Stat91 involves

dimerization through SH2-phosphotyrosyl peptide interactions. Cell 76:821-8.
122

187.

Shweiki, D., A. Itin, D. Soffer, and E. Keshet. 1992. Vascular endothelial

growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.

Nature 359:843-5.

188.

Sodhi, A., S. Montaner, V. Patel, M. Zohar, C. Bais, E. A. Mesri, and J. S.

Gutkind. 2000. The Kaposi's sarcoma-associated herpes virus G protein-coupled

receptor up-regulates vascular endothelial growth factor expression and secretion

through mitogen-activated protein kinase and p38 pathways acting on hypoxia-

inducible factor 1alpha. Cancer Res 60:4873-80.

189.

Stambolic, V., A. Suzuki, J. L. de la Pompa, G. M. Brothers, C. Mirtsos, T.

Sasaki, J. Ruland, J. M. Penninger, D. P. Siderovski, and T. W. Mak. 1998.

Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor

PTEN. Cell 95:29-39.

190.

Stein, I., M. Neeman, D. Shweiki, A. Itin, and E. Keshet. 1995. Stabilization of

vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and

coregulation with other ischemia-induced genes. Mol Cell Biol 15:5363-8.

123

191.

Stiehl, D. P., W. Jelkmann, R. H. Wenger, and T. Hellwig-Burgel. 2002.

Normoxic induction of the hypoxia-inducible factor 1alpha by insulin and

interleukin-1beta involves the phosphatidylinositol 3-kinase pathway. FEBS Lett

512:157-62.

192.

Tacchini, L., L. Bianchi, A. Bernelli-Zazzera, and G. Cairo. 1999. Transferrin

receptor induction by hypoxia. HIF-1-mediated transcriptional activation and cell-

specific post-transcriptional regulation. J Biol Chem 274:24142-6.

193.

Tacchini, L., P. Dansi, E. Matteucci, and M. A. Desiderio. 2001. Hepatocyte

growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in

HepG2 hepatoma cells. Carcinogenesis 22:1363-71.

194.

Takahashi, Y., S. Takahashi, Y. Shiga, T. Yoshimi, and T. Miura. 2000.

Hypoxic induction of prolyl 4-hydroxylase alpha (I) in cultured cells. J Biol Chem

275:14139-46.

195.

Tanimoto, K., Y. Makino, T. Pereira, and L. Poellinger. 2000. Mechanism of

regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau

tumor suppressor protein. Embo J 19:4298-309.
124

196.

Tazuke, S. I., N. M. Mazure, J. Sugawara, G. Carland, G. H. Faessen, L. F.

Suen, J. C. Irwin, D. R. Powell, A. J. Giaccia, and L. C. Giudice. 1998.

Hypoxia stimulates insulin-like growth factor binding protein 1 (IGFBP-1) gene

expression in HepG2 cells: a possible model for IGFBP-1 expression in fetal

hypoxia. Proc Natl Acad Sci U S A 95:10188-93.

197.

Teicher, B. A., S. A. Holden, G. Ara, E. A. Sotomayor, Z. D. Huang, Y. N.

Chen, and H. Brem. 1994. Potentiation of cytotoxic cancer therapies by TNP-

470 alone and with other anti-angiogenic agents. Int J Cancer 57:920-5.

198.

Terman, B. I., M. Dougher-Vermazen, M. E. Carrion, D. Dimitrov, D. C.

Armellino, D. Gospodarowicz, and P. Bohlen. 1992. Identification of the KDR

tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem

Biophys Res Commun 187:1579-86.

199.

Thomlinson, R. H., and L. H. Gray. 1955. The histological structure of some

human lung cancers and the possible implications for radiotherapy. Br J Cancer

9:539-49.

125

200.

Thornton, R. D., P. Lane, R. C. Borghaei, E. A. Pease, J. Caro, and E.

Mochan. 2000. Interleukin 1 induces hypoxia-inducible factor 1 in human

gingival and synovial fibroblasts. Biochem J 350 Pt 1:307-12.

201.

Tian, H., S. L. McKnight, and D. W. Russell. 1997. Endothelial PAS domain

protein 1 (EPAS1), a transcription factor selectively expressed in endothelial

cells. Genes Dev 11:72-82.

202.

Tischer, E., R. Mitchell, T. Hartman, M. Silva, D. Gospodarowicz, J. C.

Fiddes, and J. A. Abraham. 1991. The human gene for vascular endothelial

growth factor. Multiple protein forms are encoded through alternative exon

splicing. J Biol Chem 266:11947-54.

203.

Toi, M., T. Matsumoto, and H. Bando. 2001. Vascular endothelial growth

factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol

2:667-73.

126

204.

Treins, C., S. Giorgetti-Peraldi, J. Murdaca, G. L. Semenza, and E. Van

Obberghen. 2002. Insulin stimulates hypoxia-inducible factor 1 through a

phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J

Biol Chem 277:27975-81.

205.

Turkson, J., T. Bowman, R. Garcia, E. Caldenhoven, R. P. De Groot, and R.

Jove. 1998. Stat3 activation by Src induces specific gene regulation and is

required for cell transformation. Mol Cell Biol 18:2545-52.

206.

Vaupel, P., K. Schlenger, C. Knoop, and M. Hockel. 1991. Oxygenation of

human tumors: evaluation of tissue oxygen distribution in breast cancers by

computerized O2 tension measurements. Cancer Res 51:3316-22.

207.

Vignais, M. L., H. B. Sadowski, D. Watling, N. C. Rogers, and M. Gilman.

1996. Platelet-derived growth factor induces phosphorylation of multiple JAK

family kinases and STAT proteins. Mol Cell Biol 16:1759-69.

208.

Vivanco, I., and C. L. Sawyers. 2002. The phosphatidylinositol 3-Kinase AKT

pathway in human cancer. Nat Rev Cancer 2:489-501.

127

209.

Wang, D., H. J. Huang, A. Kazlauskas, and W. K. Cavenee. 1999. Induction of

vascular endothelial growth factor expression in endothelial cells by platelet-

derived growth factor through the activation of phosphatidylinositol 3-kinase.

Cancer Res 59:1464-72.

210.

Wang, G. L., B. H. Jiang, E. A. Rue, and G. L. Semenza. 1995. Hypoxia-

inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by

cellular O2 tension. Proc Natl Acad Sci U S A 92:5510-4.

211.

Wang, G. L., and G. L. Semenza. 1993. General involvement of hypoxia-

inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S

A 90:4304-8.

212.

Wang, G. L., and G. L. Semenza. 1995. Purification and characterization of

hypoxia-inducible factor 1. J Biol Chem 270:1230-7.

213.

Watson, C. J., and W. R. Miller. 1995. Elevated levels of members of the STAT

family of transcription factors in breast carcinoma nuclear extracts. Br J Cancer

71:840-4.

128

214.

Wei, D., X. Le, L. Zheng, L. Wang, J. A. Frey, A. C. Gao, Z. Peng, S. Huang,

H. Q. Xiong, J. L. Abbruzzese, and K. Xie. 2003. Stat3 activation regulates the

expression of vascular endothelial growth factor and human pancreatic cancer

angiogenesis and metastasis. Oncogene 22:319-29.

215.

Wei, L. H., M. L. Kuo, C. A. Chen, C. H. Chou, K. B. Lai, C. N. Lee, and C.

Y. Hsieh. 2003. Interleukin-6 promotes cervical tumor growth by VEGF-

dependent angiogenesis via a STAT3 pathway. Oncogene 22:1517-27.

216.

Weidner, N., J. P. Semple, W. R. Welch, and J. Folkman. 1991. Tumor

angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J

Med 324:1-8.

217.

Wen, Z., and J. E. Darnell, Jr. 1997. Mapping of Stat3 serine phosphorylation

to a single residue (727) and evidence that serine phosphorylation has no

influence on DNA binding of Stat1 and Stat3. Nucleic Acids Res 25:2062-7.

129

218.

Wiener, J. R., K. Nakano, R. P. Kruzelock, C. D. Bucana, R. C. Bast, Jr., and

G. E. Gallick. 1999. Decreased Src tyrosine kinase activity inhibits malignant

human ovarian cancer tumor growth in a nude mouse model. Clin Cancer Res

5:2164-70.

219.

Wiesener, M. S., J. S. Jurgensen, C. Rosenberger, C. K. Scholze, J. H.

Horstrup, C. Warnecke, S. Mandriota, I. Bechmann, U. A. Frei, C. W. Pugh,

P. J. Ratcliffe, S. Bachmann, P. H. Maxwell, and K. U. Eckardt. 2003.

Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell

populations of different organs. Faseb J 17:271-3.

220.

Wiesener, M. S., H. Turley, W. E. Allen, C. Willam, K. U. Eckardt, K. L.

Talks, S. M. Wood, K. C. Gatter, A. L. Harris, C. W. Pugh, P. J. Ratcliffe,

and P. H. Maxwell. 1998. Induction of endothelial PAS domain protein-1 by

hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha.

Blood 92:2260-8.

130

221.

Wood, J. M., G. Bold, E. Buchdunger, R. Cozens, S. Ferrari, J. Frei, F.

Hofmann, J. Mestan, H. Mett, T. O'Reilly, E. Persohn, J. Rosel, C. Schnell,

D. Stover, A. Theuer, H. Towbin, F. Wenger, K. Woods-Cook, A. Menrad, G.

Siemeister, M. Schirner, K. H. Thierauch, M. R. Schneider, J. Drevs, G.

Martiny-Baron, and F. Totzke. 2000. PTK787/ZK 222584, a novel and potent

inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs

vascular endothelial growth factor-induced responses and tumor growth after oral

administration. Cancer Res 60:2178-89.

222.

Wu, X., K. Senechal, M. S. Neshat, Y. E. Whang, and C. L. Sawyers. 1998.

The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative

regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S

A 95:15587-91.

223.

Xie, T. X., D. Wei, M. Liu, A. C. Gao, F. Ali-Osman, R. Sawaya, and S.

Huang. 2004. Stat3 activation regulates the expression of matrix

metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23:3550-60.

131

224.

Xu, L., K. Xie, N. Mukaida, K. Matsushima, and I. J. Fidler. 1999. Hypoxia-

induced elevation in interleukin-8 expression by human ovarian carcinoma cells.

Cancer Res 59:5822-9.

225.

Yahata, Y., Y. Shirakata, S. Tokumaru, K. Yamasaki, K. Sayama, Y.

Hanakawa, M. Detmar, and K. Hashimoto. 2003. Nuclear translocation of

phosphorylated STAT3 is essential for VEGF-induced human dermal

microvascular endothelial cell migration and tube formation. J Biol Chem.

226.

Yang, J. C., L. Haworth, R. M. Sherry, P. Hwu, D. J. Schwartzentruber, S. L.

Topalian, S. M. Steinberg, H. X. Chen, and S. A. Rosenberg. 2003. A

randomized trial of bevacizumab, an anti-vascular endothelial growth factor

antibody, for metastatic renal cancer. N Engl J Med 349:427-34.

227.

Yao, K. S., S. Xanthoudakis, T. Curran, and P. J. O'Dwyer. 1994. Activation

of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon

cancer cells to hypoxia. Mol Cell Biol 14:5997-6003.

132

228.

Yu, C. L., D. J. Meyer, G. S. Campbell, A. C. Larner, C. Carter-Su, J.

Schwartz, and R. Jove. 1995. Enhanced DNA-binding activity of a Stat3-related

protein in cells transformed by the Src oncoprotein. Science 269:81-3.

229.

Yu, F., S. B. White, Q. Zhao, and F. S. Lee. 2001. HIF-1alpha binding to VHL

is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci U S

A 98:9630-5.

230.

Yu, H., and R. Jove. 2004. The STATs of cancer--new molecular targets come of

age. Nat Rev Cancer 4:97-105.

231.

Yuan, F., Y. Chen, M. Dellian, N. Safabakhsh, N. Ferrara, and R. K. Jain.

1996. Time-dependent vascular regression and permeability changes in

established human tumor xenografts induced by an anti-vascular endothelial

growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A

93:14765-70.

232.

Yuan, J., and P. M. Glazer. 1998. Mutagenesis induced by the tumor

microenvironment. Mutat Res 400:439-46.

133

233.

Yuan, J., L. Narayanan, S. Rockwell, and P. M. Glazer. 2000. Diminished

DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia

and low pH. Cancer Res 60:4372-6.

234.

Zelzer, E., Y. Levy, C. Kahana, B. Z. Shilo, M. Rubinstein, and B. Cohen.

1998. Insulin induces transcription of target genes through the hypoxia-inducible

factor HIF-1alpha/ARNT. Embo J 17:5085-94.

235.

Zhang, Y. W., Y. Su, O. V. Volpert, and G. F. Vande Woude. 2003.

Hepatocyte growth factor/scatter factor mediates angiogenesis through positive

VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A

100:12718-23.

236.

Zhong, H., K. Chiles, D. Feldser, E. Laughner, C. Hanrahan, M. M.

Georgescu, J. W. Simons, and G. L. Semenza. 2000. Modulation of hypoxia-

inducible factor 1alpha expression by the epidermal growth

factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human

prostate cancer cells: implications for tumor angiogenesis and therapeutics.

Cancer Res 60:1541-5.
134

237.

Zhong, Z., Z. Wen, and J. E. Darnell, Jr. 1994. Stat3: a STAT family member

activated by tyrosine phosphorylation in response to epidermal growth factor and

interleukin-6. Science 264:95-8.

238.

Zundel, W., C. Schindler, D. Haas-Kogan, A. Koong, F. Kaper, E. Chen, A.

R. Gottschalk, H. E. Ryan, R. S. Johnson, A. B. Jefferson, D. Stokoe, and A.

J. Giaccia. 2000. Loss of PTEN facilitates HIF-1-mediated gene expression.

Genes Dev 14:391-6.

135

About the Author

Jon Briggs was born and raised in upstate New York. His initial studies were in
classical guitar, and he received a Bachelor of Fine Arts degree in music performance
from the University of South Florida in 1997. While teaching music as a private
instructor, he finished a Bachelor of Science degree in Biology in 2000. He entered the
Doctor of Philosophy program in the department of Medical Microbiology and
Immunology at USF in 2000. Jon has conducted research with his mentor Dr. Hua Yu
since 2001. This research was published in Oncogene in 2005.

